Recombinant microorganisms having improved ability to produce hydrophobic substances and cell membrane engineering methods for preparing the same

Through cell membrane engineering, the problems of low yield and environmental pollution when microorganisms produce natural hydrophobic pigments are solved, and efficient and safe pigment production is achieved.

CN114438003BActive Publication Date: 2024-11-19KOREA ADVANCED INST OF SCI & TECH
View PDF 4 Cites 0 Cited by

Patent Information

Application Number
CN202111296813.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2020-11-02
Filing Date
2021-11-01
Publication Date
2024-11-19
Estimated Expiration
2041-11-01

AI Technical Summary

Technical Problem

The prior art is difficult to effectively improve the ability of microorganisms to produce natural hydrophobic pigments, especially in the accumulation and release process in cells, resulting in low yields and environmental pollution problems.

Method used

Through cell membrane engineering, including inhibiting cell morphology-related genes, outer membrane vesicle-related genes and introducing or overexpressing endometrial vesicle-related genes, increasing cell membrane area, formation and secretion of outer membrane vesicle, and formation of endometrial vesicle to improve the formation of endometrial vesicle to improve cell membranes, so as to improve the The accumulation and release capacity of hydrophobic pigments.

Benefits of technology

It significantly improves the yield and accumulation efficiency of natural pigments, reduces environmental pollution, and achieves safer and more sustainable pigment production.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0003331558180000281
    Figure BDA0003331558180000281
  • Figure BDA0003331558180000291
    Figure BDA0003331558180000291
  • Figure BDA0003331558180000292
    Figure BDA0003331558180000292
Patent Text Reader

Abstract

Disclosed is a recombinant microorganism for producing a hydrophobic substance, wherein the recombinant microorganism undergoes cell membrane engineering to impart at least one of the characteristics of increased cell membrane area, increased formation and secretion of outer membrane vesicles, and increased formation of inner membrane vesicles; and a cell membrane engineering method for preparing the hydrophobic substance, thereby efficiently producing insoluble hydrophobic substances, and the recombinant microorganism for efficiently producing carotenoids or purple bacteriocin analogs can be used to produce natural pigments, antioxidants, antibiotics, cosmetic additives, anticancer agents, food additives or nutritional supplements, and the natural pigment production technology developed herein achieves a great improvement in production capacity. Therefore, the present invention is effective in preparing a recombinant strain for efficiently producing a variety of industrially and medically useful metabolites and establishing an efficient preparation method.
Need to check novelty before this filing date? Find Prior Art

Description

Background of the Invention Technical Field

[0001] The present invention relates to a recombinant microorganism having an improved ability to produce a hydrophobic substance and a cell membrane engineering method for preparing the hydrophobic substance, and more specifically to a recombinant microorganism for producing a hydrophobic substance, the recombinant microorganism undergoing cell membrane engineering so as to impart at least one of the characteristics of increased cell membrane area, increased formation and secretion of outer membrane vesicles, and increased formation of inner membrane vesicles; and a cell membrane engineering method for preparing the hydrophobic substance. Background Art

[0003] Due to global environmental problems, the exhaustion of non-renewable resources and the demand for eco-friendly energy, the concern of cell factories based on regeneration biology construction is gradually increased.This cell factory can be manufactured by the intracellular metabolic network for producing target metabolites (bioenergy, eco-friendly chemicals, new drugs etc.) through engineering approaches, and this requires various molecular biology techniques.The various materials produced based on petrochemicals can be divided into various categories, and one of representative classification standards is hydrophilicity and hydrophobicity.The representative group of hydrophobic substances includes hydrophobic pigments (such as carotenoids and purple bacteriocin (viortein)).Pigment is widely used in the industry including food additives, dyestuff, cosmetics, coating etc., and is inseparable from daily life.Because pigment directly affects human body when taking in or being applied to skin, therefore interest and demand to natural pigment (it is considered safer than problematic synthetic pigment based on oil) increase rapidly along with the increase of health concern in modern society.Also known synthetic pigment based on oil causes serious environmental problem when dyeing textiles. The natural pigment derived from nature also has various pharmaceutical properties except multiple colors usually, such as anticancer, antibiotic, antibacterial and immunosuppressive activity, so they may become more and more useful in daily life. At present, many pigments are produced based on petrochemicals, and natural pigments only account for a small proportion in pigment used. This has caused health problems and environmental problems, and particularly has the problem that the pigment based on petrochemicals is widely used in children's products. And, in textile dyeing process, cause serious water pollution based on the pigment of petrochemicals.

[0004] Therefore, efforts have been made to produce large amounts of natural pigments using microbial cell factories in an environmentally friendly manner, among which attempts have been reported to increase the production of hydrophobic pigments accumulated on the cell membrane by expanding the area of ​​the cell membrane (T. Wu et al., Membrane engineering-A novel strategy to enhance the production and accumulation of beta-carotene in Escherichia coli. Metab. Eng. 43, 85-91 (2017)), and attempts have been made to increase the production of hydrophobic pigments by solubilization of intracellular lipids (T. Ma et al., Lipid engineering combined with systematic metabolic engineering of Saccharomyces cerevisiae for high-yield production of lycopene. Metab. Eng. 52, 134-142 (2019)).

[0005] Against this background, the inventors have made great efforts to improve the ability to produce hydrophobic substances by modifying the inherent properties of microorganisms to produce hydrophobic substances through cell membrane engineering, and thus determined that when Escherichia coli producing carotenoids and violacein analogs as natural pigments is subjected to cell membrane engineering by inhibiting, introducing or overexpressing cell morphology-related genes, outer membrane vesicle-related genes or inner membrane vesicle-related genes, the space in which natural lipophilic pigment substances can accumulate is expanded due to the increase in cell membrane area, the increased formation and secretion of outer membrane vesicles and the increased formation of inner membrane vesicles, thereby significantly increasing the amount of natural pigments produced, and the synergistic effects of the individual elements were tested and verified, thereby ultimately achieving the present invention.

[0006] The information described in the Background section is only for improvement of understanding of the background of the invention and it should not be construed as including the information forming the relevant technology that is already known to one of ordinary skill in the art to which the invention belongs. Summary of the invention

[0007] The object of the present invention is to provide a recombinant microorganism having an improved ability to produce a hydrophobic substance through cell membrane engineering and a method for preparing the hydrophobic substance.

[0008] Another object of the present invention is to provide a method for producing a hydrophobic substance by culturing the recombinant microorganism.

[0009] Still another object of the present invention is to provide a method for screening a recombinant microorganism having a high ability to produce a specific hydrophobic substance using a recombinant microorganism library that has undergone cell membrane engineering.

[0010] In order to achieve the above object, the present invention provides a recombinant microorganism for producing a hydrophobic substance, wherein the recombinant microorganism undergoes cell membrane engineering to impart at least one of the following characteristics: increased cell membrane area, increased formation and secretion of outer membrane vesicles, and increased formation of inner membrane vesicles.

[0011] In addition, the present invention provides a method for preparing a recombinant microorganism for producing a hydrophobic substance, the method comprising inhibiting the expression of at least one of a cell morphology-related gene and an outer membrane vesicle-related gene in the recombinant microorganism for producing a hydrophobic substance, and / or introducing or overexpressing an inner membrane vesicle-related gene in the recombinant microorganism for producing a hydrophobic substance.

[0012] Furthermore, the present invention provides a method for preparing a hydrophobic substance, the method comprising producing the hydrophobic substance by culturing the recombinant microorganism for producing the hydrophobic substance that has undergone cell membrane engineering; and obtaining the produced hydrophobic substance.

[0013] In addition, the present invention provides a method for screening recombinant microorganisms that have undergone cell membrane engineering and have an improved ability to produce specific hydrophobic substances, the method comprising (a) constructing a microbial library for producing hydrophobic substances by performing cell membrane engineering in the microorganisms for producing hydrophobic substances by at least one of the following: inhibition of cell morphology-related gene expression, inhibition of outer membrane vesicle-related gene expression, and introduction or overexpression of inner membrane vesicle-related genes; and (b) selecting recombinant microorganisms with high ability to produce specific hydrophobic substances by culturing the microorganisms for producing hydrophobic substances. BRIEF DESCRIPTION OF THE DRAWINGS

[0014] The above and other objects, features and other advantages of the present invention will be more clearly understood from the following detailed description taken in conjunction with the accompanying drawings, in which:

[0015] Figure 1Schematic diagram of cell membrane engineering strategies for cell membrane space expansion and biosynthesis pathways of carotenoids and violacein analogs, where cell morphology can be changed by inhibiting the expression of related genes using a synthetic sRNA system, and outer membrane vesicles can also be formed in the same way, while inner membrane vesicles can be formed by the expression of foreign genes such as cav1, etc., and where curved arrows and T models indicate promoters and transcription terminators, respectively, solid lines and dashed lines indicate single responses and multiple responses, respectively, and abbreviations are as follows: G3P represents 3-phosphoglyceraldehyde, E4P represents 4-phosphate erythrose, PEP represents phosphoenolpyruvate, PYR represents pyruvate, DXP ​​represents 5-phosphate 1-deoxy-D-xylulose, SKM represents shikimic acid, FPP represents farnesyl diphosphate, GGPP represents geranylgeranyl pyrophosphate, TRP represents tryptophan, IPA represents indolepyruvate and Sp. represents spontaneous;

[0016] Figures 2A to 2J show the construction results of carotenoid-producing strains and the culture results of the constructed strains, Figure 2A schematically shows the plasmids of pLYC, pBTC, pZEA and pATX libraries, the curved arrows, hemispheres and T models indicate the promoter, 5'UTR and transcription terminator, respectively, Figure 2B shows the preliminary screening results of the LYC strain, Figure 2C shows the additional flask culture results of good strains after selecting conspicuous red colonies and then culturing in test tubes, Figures 2D to 2F show the results of BTC, ZEA and The test tube culture results of the ATX strain, FIG2G shows the HPLC analysis results of 50 good strain samples in FIG2F, wherein the area value of the peak corresponding to astaxanthin of each sample is plotted on the y-axis, and FIG2H, FIG2I and FIG2J respectively show the flask culture results of the BTC, ZEA and ATX strains selected from the test tube culture results, the error bars represent the mean ± standard deviation (n = 3), **P < 0.01, ***P < 0.001, NS (not significant), P ≥ 0.05 are determined by a two-tailed Student's t-test;

[0017] 3A to 3G show the results of constructing a violacetocin analog-producing strain and the results of culturing the constructed strain, FIG. 3A schematically shows a plasmid constructed for producing a violacetocin analog, FIG. 3B shows the results of comparing the amount of violacetocin produced using glucose or glycerol as a single carbon source, FIG. 3C shows the results of producing deoxyviolacetocin precursor and violacetocin precursor in PDVIO and PVIO strains using glycerol, FIG. 3D shows the results of producing deoxyviolacetocin and violacetocin in DVIO and VIO strains using glycerol, FIG. 3E and 3F show LC-MS chromatograms and spectra of deoxyviolacetocin precursor and violacetocin precursor produced from Escherichia coli strains, respectively, and FIG. 3G shows the absorption spectra of carotenoids and violacetocin analogs in the wavelength range of 350 to 750 nm, wherein each data point in the graph of FIG. 3G is an average value obtained from three independent samples, and the points are connected to form a curve graph;

[0018] Figures 4A to 4J show the results of increasing the production of carotenoids and violacein analogs by changing cell morphology and forming inner membrane vesicles, Figure 4A shows the mechanism of expanding the cell membrane space by changing the cell morphology of Escherichia coli, Figures 4B and 4C respectively show the results of producing β-carotene and deoxyviolacein by introducing sRNA that inhibits the expression of cell morphology-related genes, Figure 4D shows the formation mechanism of inner membrane vesicles in Escherichia coli, Figures 4E and 4F respectively show the results of producing β-carotene and deoxyviolacein, and Figures 4G and 4G show the results of increasing the production of β-carotene and deoxyviolacein. 4H, FIG. 4I and FIG. 4J show TEM (upper panel) and SEM (lower panel) images of the BTC1 strain as a β-carotene production control group, the β-carotene production strain expressing cav1, the DVIO strain as a deoxyviolacein production control group, and the deoxyviolacein production strain expressing cav1, the error bars in the generated graphs represent the mean ± standard deviation (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001, NS (not significant), P ≥ 0.05 were determined by a two-tailed Student's t-test;

[0019] Figures 5A and 5B show microscopic images of BTC1 and DVIO strains in which cell morphology is altered, Figure 5A shows microscopic images of the BTC1 strain and the BTC1 strain introduced with sRNA for inhibiting the expression of cell morphology-related genes, and Figure 5B shows microscopic images of the DVIO strain and the DVIO strain introduced with sRNA for inhibiting the expression of cell morphology-related genes, wherein longer or shorter cell morphology than that of the control group was observed in the strain introduced with sRNA for inhibiting the expression of cell morphology-related genes, and for each micrograph, the corresponding expression inhibition target gene is marked;

[0020] Figures 6A to 6J show the results of increasing the production of carotenoids and purple bacteriocin analogs by increasing the formation and secretion of outer membrane vesicles, Figure 6A shows the formation mechanism of outer membrane vesicles in Escherichia coli, Figures 6B and 6C show the production results of β-carotene and deoxypurpurogenous bacteriocin, respectively, Figures 6D and 6E show TEM (upper panel) and SEM (lower panel) images of the BTC1 strain introduced with sRNA that inhibits the expression of rffD and rfaD and the DVIO strain introduced with sRNA that inhibits the expression of rfaI, respectively, Figure 6F shows the purification of the outer cell vesicles formed in the BTC1 strain introduced with sRNA that inhibits the expression of rffD and rfaD (upper panel) ) and SEM images for analysis after the formation of extracellular vesicles in the DVIO strain introduced with sRNA that inhibits rfaI expression (lower inset), FIG6G shows the production result of β-carotene when both inner membrane vesicles and outer membrane vesicles are formed, FIG6H shows the production result of deoxypurobactin when a combination of cell morphology change and inner and outer membrane vesicle formation is applied, and FIG6I and FIG6J show TEM (upper inset) and SEM (lower inset) images of the BTC1 strain introduced with sRNA that inhibits rffD and rfaD expression and with cav1-plsBC, and the DVIO strain introduced with sRNA that inhibits rfaI expression and with cav1, respectively;

[0021] Figures 7A to 7L show the results of quantitative analysis of carotenoids and violacein analogs secreted into the culture medium through outer membrane vesicles, Figure 7A shows β-carotene extracted from the supernatant of the culture fluid of the BTC1 strain introduced with sRNA for expressing outer membrane vesicles (OMV), Figure 7B shows β-carotene extracted from purified outer membrane vesicles, wherein OMV indicates the BTC1 strain introduced with sRNA for inhibiting rffD and rfaD expression and IMV indicates the BTC1 strain introduced with cav1 and plsBC, Figure 7C shows deoxyviolacein extracted from the supernatant of the culture fluid of the DVIO strain introduced with sRNA for expressing outer membrane vesicles, Figure 7D shows deoxyviolacein extracted from purified outer membrane vesicles, wherein OMV indicates the DVIO strain introduced with sRNA for inhibiting rfaI expression and IMV indicates the DVIO strain introduced with cav1, 7E shows a microscope image of aggregates consisting of cells, outer membrane vesicles, and deoxyviolacetin crystals remaining after water washing during flask culture of DVIO introduced with sRNA inhibiting rfaI expression, FIG. 7F and FIG. 7G show the results of flask culture overexpressed by plsBC gene in β-carotene and deoxyviolacetin producing strains expressing outer membrane vesicles, respectively, and FIG. 7H, FIG. 7I, FIG. 7J, FIG. 7K, and FIG. 7L show graphs corresponding to the results of total production (represented by Tot) and secretory production (represented by Sec) of zeaxanthin, astaxanthin, deoxyviolacetin precursor, violacetin precursor, and violacetin when expressing outer membrane vesicles or inner membrane vesicles, respectively, wherein error bars represent mean ± standard deviation (n = 3), *P < 0.05, **P < 0.01, ***P < 0.001, NS (not significant), P ≥ 0.05 are determined by two-tailed Student's t-test; and

[0022] 8A to 8G show the results of producing corresponding hydrophobic substances such as astaxanthin, β-carotene, zeaxanthin, violacein precursor, deoxyviolacein precursor, violacein, and deoxyviolacein over time when the recombinant microorganism of the present invention is used for fed-batch fermentation. DETAILED DESCRIPTION

[0023] Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs. Generally, the nomenclature used herein is well known and typical in the art.

[0024] Unless otherwise indicated, nucleic acids are listed from left to right in a 5'→direction, and amino acids are listed from left to right in an N-terminus→C-terminus direction.Numerical ranges recited within the specification are inclusive of the numbers defining the range, including each integer or any non-integer fraction within the defined range.

[0025] To date, many attempts have been made to increase the production of colored natural substances by manipulating the metabolic network of microorganisms, but some limitations have been imposed on them due to the characteristics of the accumulation of substances in cells. In the present invention, the amount of hydrophobic pigment produced is greatly increased by engineering the cell membrane in various ways to expand the cell membrane area, expanding the cell membrane by generating structures inside the cell, or capturing the corresponding substances in vesicles to release them out of the cell.

[0026] In one embodiment of the present invention, natural pigments such as carotenoids and purple bacteriocin analogs are produced in Escherichia coli. Carotenoids and purple bacteriocin analogs are lipophilic substances, which accumulate in the cell membrane rather than in the cytoplasm or outside the cell when produced in Escherichia coli. Based on this, increase the cell membrane area and form vesicles inside and outside the cell, so that the space that the expanded natural lipophilic pigment material can accumulate. Specifically, construct an Escherichia coli strain that produces each of three types of carotenoids and four types of purple bacteriocin analogs, and observe the change of the increase of the cell membrane area and the formation of vesicles afterwards. And, test and verify the synergistic effect of the individual elements of the present invention in the generation of all materials. The strategy used in the present invention's research can be efficiently applied to the research of the production of natural pigments and a variety of different lipophilic substances such as antioxidants, antibiotics, cosmetic additives, anticancer agents, food additives and nutritional supplements in Escherichia coli.

[0027] In one embodiment of the present invention, a hydrophobic substance producing strain capable of producing the most frequently used natural pigments in industry (such as carotenoids and purple bacteriocin) is constructed, and with the goal of improving the ability to produce hydrophobic substances, the hydrophobic substance producing strain is subjected to cell membrane engineering so as to exhibit characteristics such as: i) increased cell membrane area, ii) increased formation and secretion of outer membrane vesicles, or iii) increased formation of inner membrane vesicles. In order to impart the above characteristics to the strain through cell membrane engineering, cell morphology-related genes and outer membrane vesicle-related genes are screened, and when the expression of the corresponding gene is inhibited by treating with sRNA targeting cell morphology-related genes or outer membrane vesicle-related genes or when the inner membrane vesicle-related genes are overexpressed, it is confirmed that the ability of the strain to produce natural pigments is significantly improved, and the combination of gene expression inhibition and overexpression exhibits a synergistic effect.

[0028] In one embodiment of the present invention, it has been confirmed that the increase in cell membrane area caused by inhibiting cell morphology-related genes in Escherichia coli, the increase in the formation and secretion of outer membrane vesicles caused by inhibiting outer membrane vesicle-related genes, and the increase in the formation of inner membrane vesicles caused by overexpressing inner membrane vesicle-related genes lead to a significant improvement in the ability to produce natural pigments, which are representative hydrophobic substances accumulated in cell membranes. In general, it is easy to understand that hydrophobic substances accumulate in the inner and outer membranes of hydrophobic cell membranes or vesicles, and therefore various hydrophobic substances other than natural pigments that can be produced by microorganisms can be produced at a level equivalent to the ability to produce natural pigments.

[0029] Therefore, the present invention relates to a recombinant microorganism for producing a hydrophobic substance, which has undergone cell membrane engineering to impart at least one of the following characteristics: increased cell membrane area, increased formation and secretion of outer membrane vesicles, and increased formation of inner membrane vesicles.

[0030] As used herein, the term "cell membrane engineering" refers to a technique that uses gene recombination technology, etc. to enhance or reduce conventional cell membrane characteristics of cells or to impart new characteristics to them. In the present invention, cell membrane engineering is performed by inhibiting, overexpressing and / or introducing genes, and is intended to impart the following characteristics: increase cell membrane area, increase the formation and secretion of outer membrane vesicles, and / or increase the formation of inner membrane vesicles.

[0031] In one embodiment of the present invention, the above characteristics are imparted by cell membrane engineering through gene expression inhibition, introduction or overexpression in a recombinant microorganism for producing a hydrophobic substance.

[0032] Therefore, one aspect of the present invention relates to a recombinant microorganism for producing a hydrophobic substance, wherein at least one of a cell morphology-related gene and an outer membrane vesicle-related gene is suppressed and / or wherein an inner membrane vesicle-related gene is overexpressed or introduced.

[0033] In the present invention, a recombinant microorganism is engineered by suppressing at least one of cell morphology-related genes and outer membrane vesicle-related genes and / or overexpressing or introducing inner membrane vesicle-related genes, so as to confer at least one of the following characteristics to the recombinant microorganism: i) increased cell membrane area, ii) increased formation and secretion of outer membrane vesicles, and iii) increased formation of inner membrane vesicles.

[0034] In the present invention, the hydrophobic substance may be characterized by accumulation in the cell membrane.Examples of the hydrophobic substance may include, but are not limited to, natural pigments, antioxidants, antibiotics, cosmetic additives, anticancer agents, food additives, and nutritional supplements.

[0035] In the present invention, natural pigments are pigments or their analogs that are not artificially synthesized but can be obtained from nature, examples of which may include carotenoids, violacein, etc., and specific examples may include but are not limited to lycopene, β-carotene, zeaxanthin, astaxanthin, violacein precursor (PVIO), deoxyviolacein precursor (PDVIO), deoxyviolacein (DVIO), violacein (VIO), etc.

[0036] Examples of antioxidant substances may include, but are not limited to, quercetin, dihydroquercetin, kaempferol, dihydrokaempferol, astaxanthin, resveratrol, tocopherol, tocotrienol, coenzyme Q10, apigenin, and the like.

[0037] Examples of cosmetic additives may include, but are not limited to, aloesin, vitamin A, ceramide, pantothenate, panthenol, lupeol, squalene, eucalyptol, valencene, and the like.

[0038] Examples of food additives may include, but are not limited to, carminic acid, β-carotene, lycopene, and the like.

[0039] Examples of nutritional supplements may include, but are not limited to, silymarin, lutein, vitamins, coenzyme-Q10, resveratrol, omega-3 polyunsaturated fatty acids, ubiquinone, glucosamine, luteolin, and the like.

[0040] In the present invention, the hydrophobic substance is preferably selected from the group consisting of astaxanthin, β-carotene, zeaxanthin, violacein precursor, deoxyviolacein precursor, deoxyviolacein and violacein.

[0041] As used herein, the term "cell morphology-related gene" refers to a gene involved in maintaining cell morphology, and in one embodiment of the present invention, the expression of the cell morphology-related gene is inhibited so as to increase the area of ​​the cell membrane in which the hydrophobic substance accumulates by making the filamentous recombinant cell morphology more irregular or more spherical. In the present invention, any cell morphology-related gene may be included but is not limited to, as long as it is a gene that can increase the cell area by changing the cell morphology when its expression is inhibited. Depending on the type of recombinant microorganism used, a person skilled in the art can easily select such a gene, and the gene is preferably selected from the gene required to form, maintain or change the intrinsic cell morphology of the recombinant microorganism, but the present invention is not limited thereto.

[0042] In the present invention, the cell morphology-related gene may be, for example, a gene involved in cell division or a gene involved in the synthesis or maintenance of the cytoskeleton / cell wall, but is not limited thereto.

[0043] In the present invention, the gene involved in cell division may be a gene encoding a group of prokaryotic enzymes involved in cell division, the prokaryotic enzyme group including, for example, cell division proteins (such as Fts proteins, etc.) and cell division inhibitors (such as MinC, MinD, etc.), but not limited thereto.

[0044] In the present invention, the genes involved in the synthesis or maintenance of the cytoskeleton / cell wall may be genes encoding a prokaryotic enzyme group, the prokaryotic enzyme group including, for example, penicillin binding protein (PBP), cell shape determining protein (MreB, MreC, etc.), peptidoglycan D,D-transpeptidase (MrdA, PbpA, etc.), peptidoglycan glycosyltransferase (MrdB, etc.), cytoskeleton protein (RodZ, etc.), etc., but are not limited thereto.

[0045] In one embodiment of the present invention, after preparing recombinant E. coli expressing natural pigments, cell membrane engineering is performed by inhibiting the expression of 16 types of screened cell morphology-related genes (Table 4). For example, when the recombinant microorganism is Escherichia coli, the cell morphology-related gene can be selected from rodZ (cytoskeleton protein), ftsA (cell division protein), ftsB (cell division protein), ftsI (peptidoglycan D, D-transpeptidase), ftsL (cell division protein), ftsQ (cell division protein), ftsW (possible peptidoglycan glycosyltransferase), ftsZ (cell division protein), minD (septum site determining protein), mrdA (peptidoglycan D, D-transpeptidase), mrdB (peptidoglycan glycosyltransferase), mreB (cell shape determining protein), mreC (cell shape determining protein), zipA (cell division protein), murE (UDP-N-acetylmuramoyl-L-alanyl-D-glutamate-2,6-diaminopimelate ligase), pbpC (penicillin binding protein 1C) and a combination thereof, but are not limited thereto.

[0046] More preferably, for example, the deoxyviolacein-producing recombinant Escherichia coli is characterized in that the expression of the mrdB gene, which is a cell morphology-related gene, is suppressed.

[0047] In the present invention, the cell morphology-related gene can be appropriately changed or selected from a gene corresponding to the Escherichia coli cell morphology-related gene inhibited in the embodiment of the present invention or a gene performing substantially the same function, depending on the microorganism used and the hydrophobic substance to be produced.

[0048] As used herein, the term "outer membrane vesicle-related gene" refers to a gene that participates in the formation or secretion of an outer membrane vesicle. In the present invention, the outer membrane vesicle-related gene can be an endogenous gene of a microorganism. In one embodiment of the invention, when the hydrophobic substance accumulated by the outer membrane vesicle in the cell is released by suppressing the expression of a gene (it is an outer membrane vesicle-related gene) that works in the connection between the outer membrane and the inner membrane of the cell or the peptidoglycan layer of the cell, the ability to produce hydrophobic substances is significantly improved. In the present invention, any outer membrane vesicle-related gene can be included without limitation, as long as it is a gene that can improve the formation and secretion of the outer membrane vesicle when suppressed expression. This gene can be easily selected according to the type of the recombinant microorganism used, and is preferably a gene that participates in the connection between the outer membrane and the inner membrane of the cell or the peptidoglycan layer of the cell, but is not limited thereto.

[0049] In the present invention, the outer membrane vesicle-related gene may be an outer membrane / peptidoglycan structure maintenance-related gene, an outer membrane protein expression gene or a cell membrane metabolic network-related gene, but is not limited thereto.

[0050] In the present invention, the outer membrane / peptidoglycan structure maintenance-related genes may be genes encoding a group of prokaryotic enzymes that help maintain the outer membrane / peptidoglycan structure, such as lipoprotein (Lpp), Tol-Pal system proteins (TolB, Pal, TolA, TolR, etc.), lipopolysaccharide core biosynthesis protein, lipopolysaccharide core heptosyltransferase, lipid A biosynthesis lauroyltransferase, etc., but are not limited thereto.

[0051] In the present invention, the outer membrane protein expression gene can be a gene encoding a prokaryotic enzyme group that contributes to the expression of the outer membrane protein, such as outer membrane protein A (OmpA), outer membrane protein C (OmpC), outer membrane protein F (OmpF), OprF (OmpA homolog), envelope protein (RagA, RagB, etc.), etc., but is not limited to this.

[0052] In the present invention, the cell membrane metabolic network-related genes may be associated with the expression of anti-sigma factors.

[0053] In the present invention, the cell membrane metabolic network related genes may be genes encoding a cell membrane metabolic network enzyme group derived from prokaryotes, such as quinolone signal (PQS), anti-σ-E factor, σ factor H (AlgU), molecular chaperone protease (DegP), etc., but are not limited thereto.

[0054] In one embodiment of the present invention, after preparing a recombinant Escherichia coli expressing a natural pigment, cell membrane engineering is performed by inhibiting the expression of 26 screened outer membrane vesicle-related genes (Table 7). For example, when the recombinant microorganism is Escherichia coli, the outer membrane vesicle-related genes can be selected from rseA (anti-σ-E factor), rseB (σ-E factor regulatory protein), rffD (UDP-N-acetyl-D-mannosamine dehydrogenase), rffC (dTDP-fucosamine acetyltransferase), rffA (dTDP-4-amino-4,6-dideoxygalactose aminotransferase), ompR (DNA binding dual transcriptional regulator), gmhB (D-glycerol-β-D-mannose-heptose-1,7-bisphosphate 7-phosphatase) , lpxL (lipid A biosynthesis lauroyltransferase), lpxM (lipid A biosynthesis myristoyltransferase), ompA (outer membrane protein), ompC (outer membrane protein), rfaB (lipopolysaccharide 1,6-galactosyltransferase), rfaC (lipopolysaccharide heptosyltransferase 1), rfaD (ADP-L-glycerol-D-mannose-heptose-6-epimerase), rfaE (bifunctional protein HldE), rfaG (lipopolysaccharide core biosynthesis protein), rfaI (lipopolysaccharide 1,3-galactosyltransferase )、rfaJ(lipopolysaccharide 1,2-glucosyltransferase), rfaK(lipopolysaccharide 1,2-N-acetylglucosamine transferase), rfaP(lipopolysaccharide core heptose (I) kinase), rfaQ(lipopolysaccharide core heptose (II) kinase), rfbA(glucose-1-phosphate thymidine transferase 1), rffH(glucose-1-phosphate thymidine transferase 2), wzxE(ECA polysaccharide chain length regulatory protein), pnp(polyribonucleotide nucleotidyltransferase), tol A (colicin import membrane protein), tolB (Tol-Pal system periplasmic protein), tolC (outer membrane protein), tolR (biopolymer transporter), nlpI (lipoprotein), nlpD (murein hydrolase activating factor), ompF (outer membrane porin), pal (peptidoglycan-associated outer membrane lipoprotein), degS (serine endoproteinase), degP (serine endoproteinase), tatC (sec-independent protein translocase protein), lpp (murein lipoprotein) and combinations thereof, but are not limited thereto.

[0055] For example, in recombinant E. coli producing carotenoids (such as astaxanthin, β-carotene or zeaxanthin), the expression of at least one gene selected from rfaD, rffD and rfaQ can be suppressed, and preferably, the expression of rffD and rfaD genes has been suppressed.

[0056] In another example, in the recombinant Escherichia coli producing violacein and its analogs (such as violacein, deoxyviolacein precursor, violacein precursor or deoxyviolacein), the expression of rfaI or rfaQ gene can be inhibited, and preferably, the expression of rfaI gene can be inhibited.

[0057] In the present invention, the outer membrane vesicle-related gene can be appropriately changed or selected from a gene corresponding to the outer membrane vesicle-related gene inhibited in the embodiment of the present invention or a gene performing substantially the same function, depending on the microorganism used and the hydrophobic substance to be produced.

[0058] As used herein, the term "inner membrane vesicle-related gene" refers to a gene involved in the formation of inner membrane vesicles, and in one embodiment of the present invention, since Escherichia coli (which is a prokaryotic organism without an inner membrane vesicle system) is used, cell membrane engineering is performed so that the inner membrane is formed by introducing a human-derived caveolae gene of an inner membrane vesicle system of eukaryotic origin. In the present invention, any inner membrane vesicle-related gene can be selected and used without restriction, as long as it is a gene that can improve the formation of inner membrane vesicles. In the present invention, when the recombinant microorganism used to produce a hydrophobic substance is a microorganism that does not have an inner membrane vesicle system, another inner membrane vesicle system gene of a eukaryotic or prokaryotic origin that forms the inner membrane can be introduced. In the present invention, when the recombinant cell used to produce a hydrophobic substance inherently includes an inner membrane vesicle system, the inner membrane vesicle gene of the cell itself can be overexpressed, or another inner membrane vesicle system gene of a eukaryotic or prokaryotic origin can be additionally introduced.

[0059] In the present invention, the inner membrane vesicle-related gene can be a caveolin system gene or a clathrin-epsin system gene derived from a eukaryotic cell, or can be a mgs-dgs system gene derived from a prokaryotic cell, and can be more specifically selected from cav1 (caveolin-1), cav2 (caveolin-2), cav3 (caveolin-3), EPN1 (epsin1), CLINT1 (epsinR), CLTC (clathrin heavy chain 1), CLTCL1 (clathrin heavy chain 2), CLTA (clathrin light chain A), CLTB (clathrin light chain B), AP180, AP2, almgs (1,2-diacylglycerol 3-glucosyltransferase), aldgs (1,2-diacylglycerol-3-glucose (1-2)-glucosyltransferase producing diglucosyldiacylglycerol) and a combination thereof, but is not limited thereto.

[0060] In the present invention, the cav1 gene can be introduced or overexpressed in the recombinant Escherichia coli that produces carotenoids (such as astaxanthin, β-carotene, zeaxanthin).

[0061] In the present invention, the cav1 gene may be introduced or overexpressed in the recombinant Escherichia coli producing violacein or its analogs (violacein precursor, deoxyviolacein precursor and deoxyviolacein).

[0062] In the present invention, the inner membrane vesicle-related gene can be appropriately changed or selected according to the microorganism used and the hydrophobic substance to be produced.

[0063] In one embodiment of the present invention, it has been confirmed that the combination of inhibition of cell morphology-related gene expression, inhibition of outer membrane vesicle-related gene expression and introduction of inner membrane vesicle-related gene shows a synergistic effect, resulting in a greater increase in production amount.

[0064] In the present invention, characteristics such as increased cell membrane area, increased formation and secretion of outer membrane vesicles, increased formation of inner membrane vesicles, etc. can be exhibited together through cell membrane engineering, depending on the type of recombinant microorganism and the type, amount, expression conditions, etc. of the hydrophobic substance produced.

[0065] In the present invention, the inhibition of cell morphology-related gene expression, the inhibition of outer membrane vesicle-related gene expression and the introduction or overexpression of inner membrane vesicle-related genes can be combined according to the type of recombinant microorganism and the type, amount, expression conditions, etc. of the hydrophobic substance to be produced, and genes belonging to individual related genes can be combined.

[0066] In the present invention, the recombinant microorganism is characterized in that: i) at least one gene selected from mrdB, rffD, rfaD and rfaI is suppressed or knocked down, and / or ii) the cav1 gene has been introduced or overexpressed.

[0067] The combinations of gene suppression and introduction / overexpression that showed the maximum production capacity in the recombinant microorganism for producing each hydrophobic substance confirmed in the embodiments of the present invention are as follows:

[0068] Astaxanthin: rffD and rfaD knockdown (OMV);

[0069] β-carotene: rffD and rfaD knockdown (OMV);

[0070] Zeaxanthin: rffD and rfaD knockdown (OMV);

[0071] Violet bacteriocin precursor: rfaI knockdown and cav1 overexpression (OMV and IMV);

[0072] Deoxypurpurogenin precursor: rfaI knockdown (OMV);

[0073] Violacin: rfaI knockdown and cav1 overexpression (OMV and IMV); and

[0074] Deoxypurpurogenin: rfaI knockdown and cav1 overexpression (OMV and IMV).

[0075] Therefore, in the present invention, in the recombinant microorganism producing the carotenoid pigment group, it is most preferred to suppress the expression of rfaD and rffD at the same time, but the present invention is not limited thereto.

[0076] In the present invention, in the recombinant microorganisms producing violacein and its analogs, it is most preferred to inhibit the expression of rfaI and simultaneously introduce the cav1 gene or induce its overexpression, but the present invention is not limited thereto.

[0077] The recombinant strain for producing a hydrophobic substance according to the present invention may be endowed with at least one of the following characteristics: increased cell membrane area, increased formation and secretion of outer membrane vesicles, and increased formation of inner membrane vesicles.

[0078] In one embodiment of the present invention, the expression of the plsBC gene as a lipid synthase gene is amplified to promote lipid supply in response to increased cell membrane area, increased formation and secretion of outer membrane vesicles, and increased formation of inner membrane vesicles. Thus, it was confirmed that the ability to produce carotenoid pigments was significantly improved.

[0079] In the present invention, the recombinant microorganism for producing a hydrophobic substance is further characterized by overexpressing a lipid synthase gene.

[0080] For example, when the microorganism is Escherichia coli, overexpression of the lipid synthase gene may be overexpression of the plsBC gene.

[0081] As used herein, the term "inhibition of gene expression" refers to inhibiting or regulating the transcription or translation of the gene to be inhibited, thereby reducing or blocking the expression of the encoded protein or preventing the protein from functioning correctly, thereby losing the function of the gene. In the present invention, the term "inhibition" can be used interchangeably with "knockdown". In the present invention, the expression of cell morphology-related genes can be inhibited to increase the cell membrane area, and in order to increase the formation and secretion of outer membrane vesicles, the expression of outer membrane / peptidoglycan structure-maintaining related genes, outer membrane protein expression genes, or cell membrane metabolic network-related genes can be inhibited. In the present invention, the inhibition of gene expression can be carried out by a variety of conventionally known methods. For example, gene expression can be inhibited by gene editing using restriction enzymes, ZFN, TALEN or CRISPR / Cas, antisense oligonucleotides (Nature Reviews Drug Discovery 11(2):125-40), ribozymes (Human Molecular Genetics, 7(10):1649-1653), RNA interference technology using synthetic regulatory sRNAs such as siRNA, miRNA, shRNA, etc. (Na et al., Nat. Biotechnol. 2013, 31(2):170-174), etc., but the present invention is not limited thereto.

[0082] As used herein, the term "gene introduction" refers to the introduction of a new target gene or a vector comprising the new target gene into a target cell or microorganism. In one embodiment of the invention, for gene introduction, a plasmid vector is used to introduce a gene encoding a natural pigment into Escherichia coli to construct a natural pigment producing strain, and a plasmid vector is used to introduce an inner membrane vesicle-related gene into a recombinant microorganism to promote the formation of inner membrane vesicles. In the present invention, genes can be introduced into recombinant microorganisms by any of the various methods known in the relevant art. In the present invention, introduction is preferably introduced into a microorganism using a vector, but the present invention is not limited thereto. In the present invention, genes can be directly introduced into the genome of a host cell, and therefore can exist as a chromosomal factor. It is clear to a technician in the field of the present invention that even when a gene is inserted into the genomic chromosome of a host cell, the same effect as when a recombinant vector is introduced into a host cell can be exhibited.

[0083] As used herein, the term "overexpression" of a gene means that the expression of the gene is increased compared to an unmodified microorganism, thereby resulting in an increase in the intracellular concentration of ribonucleic acid, protein or enzyme compared to an unmodified microorganism. Those skilled in the art can select and carry out a variety of conventionally known gene overexpression methods without limitation.

[0084] Examples of conventionally known overexpression techniques are as follows:

[0085] - increasing the copy number of a gene in a microorganism, wherein the gene is encoded on the chromosome or extrachromosomally, and when the gene is located on the chromosome, several copies of the gene can be introduced on the chromosome by recombination methods known to those skilled in the art (including gene replacement), while when the gene is located extrachromosomally, it can be carried by various types of plasmids, which differ in the origin of replication in the cell and in their copy number, these plasmids being present in the microorganism in 1 to 5 copies, about 20 copies or up to 500 copies, depending on the characteristics of the plasmid: low-copy number plasmids with intensive replication (pSC101, RK2), low-copy number plasmids (pACYC, pRSF1010) or high-copy number plasmids (pSK bluescript II);

[0086] - use of promoters leading to high gene expression, among which a wide range of promoters can be used, for example Ptrc, Ptac, Plac or lambda promoters PR and PL, but the present invention is not limited thereto, said promoters being "inducible" by certain compounds or under certain external conditions such as temperature or light, and said promoters being homologous or heterologous;

[0087] - Attenuate the activity or expression of a specific or non-specific transcriptional repressor of a gene;

[0088] - use of elements that stabilize the corresponding messenger RNA (Carrier and Keasling, 1999) or elements that stabilize the protein (e.g. GST tag, GE Healthcare); and

[0089] - Changing the sequence of the 5' untranslated region (5'UTR), but the present invention is not limited thereto.

[0090] As used herein, the term "vector" refers to a nucleic acid molecule that contains a nucleotide sequence operably connected to a suitable expression control sequence that can express a gene in a suitable host. The vector can be a plasmid, a phage particle, or a potential genome insert. After being transformed into a suitable host, the vector can replicate and function independently of the host genome, or can be integrated into the genome itself in some cases. Since plasmid is the most commonly used vector form at present, "plasmid" and "vector" are sometimes used interchangeably in the context of the present invention. However, the present invention includes other forms of vectors that are functionally equivalent to those known in the art or becoming known. Examples of protein expression vectors used in Escherichia coli may include pET series, pCDF series, pRSF series, pACYC series, and pCOLA series available from Novagen (USA); pBAD series available from Invitrogen (USA); pHCE or pCOLD available from Takara (Japan); pACE series available from Xenofocus (Korea); pTac15K, pTrc99A, pTacCDFS, and pTrcCDFS series available from KAIST (Korea); pBBR1MCS series that can be used in a wide range of strains, etc. In Bacillus subtilis, protein expression can be achieved by inserting the target gene into a certain part of the genome, or pHT vectors available from MoBiTech (Germany) etc. can be used. In molds or yeast, proteins can be expressed using genome insertion or self-replicating vectors. Plant protein expression vectors can be used using a T-DNA system such as Agrobacterium tumefaciens or Agrobacterium rhizogenes. Typical expression vectors for mammalian cell culture expression can be based on, for example, pRK5 (EP307,247), pSV16B (WO 91 / 08291) and pVL1392 (Pharmingen).

[0091] The expression "expression control sequence" refers to a DNA sequence necessary for expressing an operably linked coding sequence in a certain host organism. Such control sequences include a promoter for transcription, any operator sequence for regulating such transcription, a sequence encoding a suitable mRNA ribosome binding site, and a sequence for regulating transcription and translation termination. For example, control sequences suitable for prokaryotes include a promoter, any operator sequence, and a ribosome binding site. Eukaryotic cells include a promoter, a polyadenylation signal, and an enhancer. The factor that most affects the expression level of a gene in a plasmid is the promoter. Preferred examples of promoters for high expression include the SRα promoter and a promoter derived from cytomegalovirus.

[0092] In order to express the DNA sequence of the present invention, any of a variety of expression control sequences can be used in the vector. In addition to the promoters described above, examples of useful expression control sequences include early and late promoters of SV40 or adenovirus, lac system, trp system, TAC or TRC system, T3 and T7 promoters, major operator and promoter regions of bacteriophage λ, control regions encoding fd proteins, promoters for 3-phosphoglycerate kinase or other glycolytic enzymes, promoters for phosphatases (such as Pho5), promoters of yeast α-mating system, and other constitutive and inducible promoter sequences known to control the expression of genes in prokaryotic or eukaryotic cells or their viruses, and various combinations thereof. T7 RNA polymerase promoter Φ can be used to express proteins in Escherichia coli.

[0093] It is naturally understood that not all vectors and expression control sequences work equally when expressing the DNA sequence of the present invention. Likewise, not all hosts work equally in the same expression system. However, those skilled in the art can make appropriate choices from various vectors, expression control sequences and hosts without departing from the scope of the present invention without excessive experimental burden. For example, when selecting a vector, the host must be considered. This is because the vector must replicate therein. The copy number of the vector, its ability to control the copy number, and the expression of other proteins (e.g., antibiotic markers) encoded by the vector must also be considered. When selecting an expression control sequence, various factors must be considered. For example, particularly with respect to possible secondary structures, the relative strength of the sequence, the possibility of its control, and compatibility with the DNA sequence of the present invention should be considered. A unicellular host should be selected in view of the following factors: such as the selected vector, the toxicity of the product encoded by the DNA sequence of the present invention, the secretion characteristics, the ability to correctly fold proteins, the culture and fermentation requirements, and the ease of purifying the product encoded by the DNA sequence of the present invention from the host. Within the scope of these factors, those skilled in the art can select various combinations of vectors, expression control sequences, and hosts that can express the DNA sequence of the present invention in fermentation or large animal culture. As a screening method for cloning cDNA by expression cloning, a binding method, a panning method, a membrane emulsion method, etc. can be applied.

[0094] In such vectors, when a nucleic acid is in a functional relationship with another nucleic acid sequence, the nucleic acid can be said to be "operably linked". It can be a gene and one or more control sequences connected in such a way that an appropriate molecule (e.g., a transcriptional activator) allows gene expression when combined with one or more control sequences. For example, the DNA of a presequence or secretory leader sequence is operably linked to the DNA of a polypeptide when expressed as a preprotein involved in the secretion of the polypeptide; a promoter or enhancer is operably linked to the sequence when affecting the transcription of the coding sequence; a ribosome binding site is operably linked to the sequence when affecting the transcription of the coding sequence; or a ribosome binding site is operably linked to the coding sequence when positioned to promote translation. Generally speaking, "operably linked" means that the connected DNA sequence is in contact with it, and also refers to the secretory leader sequence in contact with it and present in the reading frame. However, the enhancer does not need to be in contact with it. The connection of these sequences is achieved by connection at a convenient restriction enzyme site. When such a site is not present, a synthetic oligonucleotide adapter or joint is used according to a typical method.

[0095] The recombinant vector can be introduced into the host cell using methods such as transformation or transfection. As used herein, the term "transformation" refers to the introduction of DNA into the host so that the DNA becomes replicable as an extrachromosomal factor or by chromosomal integration. As used herein, the term "transfection" refers to the acceptance of an expression vector by a host cell, regardless of whether any coding sequence is actually expressed.

[0096] As is well known in the art, in order to increase the expression level of the transfected gene in the recombinant cell, the corresponding gene must be operably linked to the transcription and translation expression control sequences that play a role in the selected expression host. Preferably, the expression control sequence and the corresponding gene are contained in a single expression vector that includes both a bacterial selection marker and an origin of replication. When the expression host is a eukaryotic cell, the expression vector may also include an expression marker useful in the eukaryotic expression host.

[0097] In the present invention, as the microorganism for producing hydrophobic substances, prokaryotic cells such as Escherichia coli, Bacillus subtilis, etc. have been widely used, and the prokaryotic cells can be cultured at high concentrations in a short time, are easy to genetically manipulated, and have well-known genetic and physiological characteristics. In addition to prokaryotic cells, recently, unicellular eukaryotic cells, such as yeast (Pichia pastoris, Saccharomyces cerevisiae, Hansenula polymorpha, etc.), filamentous fungi, insect cells, plant cells, cells of higher organisms such as mammals, etc., can also be used as host cells for producing recombinant proteins, so as to solve the problems of post-translational modification, secretion process, active three-dimensional structure and protein activity state of proteins. Not only the use of Escherichia coli or recombinant microorganisms illustrated in the embodiments, but also the use of other host cells will be easy to understand for those skilled in the art. For example, CHO cell line, HEK cell line, etc. can be used as host cells for expression, but the present invention is not limited thereto.

[0098] In the present invention, a wide variety of microorganisms / host cells and vector combinations can be used. Expression vectors for eukaryotic hosts include, for example, expression control sequences derived from SV40, bovine papilloma virus, adenovirus, adeno-associated virus, cytomegalovirus, and retrovirus. Expression vectors that can be used in bacterial hosts include bacterial plasmids, such as those obtained from E. coli (such as pBluescript, pGEX2T, pUC vectors, col E1, pCR1, pBR322, pMB9 and derivatives thereof), broad host range bacterial plasmids (such as pBBR1MCS and derivatives thereof), bacterial plasmids such as pET, pCDF, pRSF, pACYC, pCOLA, pBAD, pHCE, pCOLD, pACE, pTac15K, pTrc99A, pTacCDFS, pTrcCDFS and derivatives thereof, plasmids that can be used for a broad host range (such as RP4); phage DNA, such as various phage lambda derivatives (such as lambda and lambda NM989) and other DNA phages (such as M13 and filamentous single-stranded DNA phages). Expression vectors that can be used for yeast cells are 2μ plasmids and derivatives thereof. A vector that can be used for insect cells is pVL 941.

[0099] In the present invention, the recombinant microorganism for producing hydrophobic substances is a microorganism that contains an endogenous or exogenous gene encoding a hydrophobic substance and thus has the ability to express a hydrophobic substance. When the gene encoding the hydrophobic substance is an exogenous gene, the expression microorganism or the recombinant expression microorganism that is given the ability to produce by introduction into the expression cell can be subjected to cell membrane engineering. Various methods for introducing exogenous genes into microorganisms are known in the relevant art, and non-limiting examples thereof include transformation, transduction, etc., and a suitable method can be selected by those skilled in the art to prepare a microorganism that produces a hydrophobic substance.

[0100] In the present invention, the recombinant microorganism is preferably selected from Escherichia coli, Rhizobium, Bifidobacterium, Rhodococcus, Candida, Erwinia, Enterobacter, Pasteurella, Mannheimia, Actinobacillus, Aggregatibacter, Xanthomonas, Vibrio, Pseudomonas, Azotobacter, Acinetobacter, The present invention relates to bacteria of the genera Ralstonia, Agrobacterium, Rhodobacter, Zymomonas, Bacillus, Staphylococcus, Lactococcus, Streptococcus, Lactobacillus, Clostridium, Corynebacterium, Streptomyces, Bifidobacterium, Cyanobacterium and Cyclobacterium, but is not limited thereto.

[0101] As used herein, the term "endogenous gene" means that the gene is present in the microorganism before any genetic modification. Endogenous genes can be overexpressed in the following ways: in addition to endogenous regulatory elements, heterologous sequences are introduced by introducing or replacing endogenous regulatory elements, or one or more complementary copies of genes are introduced into chromosomes or plasmids. Endogenous genes can also be modified to regulate the expression and activity of the encoded protein corresponding thereto. For example, mutations can be introduced into the coding sequence to modify the gene product, or heterologous sequences can be introduced by introducing or replacing endogenous regulatory elements in addition to endogenous regulatory elements. The regulation of endogenous genes can result in the increase and / or enhancement of gene product activity, or alternatively, the activity of endogenous gene products can be lowered and / or reduced.

[0102] Another way to regulate expression is to exchange the endogenous promoter (e.g., wild-type promoter) of the gene with a stronger or weaker promoter to up-regulate or down-regulate the expression of the endogenous gene. These promoters can be homologous or heterologous. The selection of an appropriate promoter is entirely within the capabilities of those skilled in the art.

[0103] In contrast, the term "exogenous gene" means that a gene is introduced into a microorganism by means well known to those skilled in the art and the gene is not naturally present in the microorganism. Exogenous genes can be integrated into the host chromosome, or can be expressed extrachromosomally by a plasmid or vector. Various plasmids that differ in their origin of replication and copy number in the cell are well known in the art. These genes can be homologous.

[0104] As used herein, the term "homologous gene" is not limited to designating genes having a theoretical common genetic ancestor, but includes genes that, although genetically unrelated, have evolved to encode proteins that perform similar functions and / or have similar structures. Therefore, for the purposes of the present invention, the term "functional homolog" relates to the fact that certain enzyme activities can be provided not only by a specific protein with a determined amino acid sequence, but also by proteins with similar sequences from other (non) related microorganisms.

[0105] Using the references given in GenBank about known genes, those skilled in the art can determine equivalent genes in other organisms, bacterial strains, yeasts, fungi, mammals, plants, etc. This routine work is advantageously performed using consensus sequences, which can be determined by comparing sequences with genes derived from other microorganisms and designing degenerate probes to clone the corresponding gene in another organism. These conventional methods of molecular biology are well known to those skilled in the art.

[0106] Another aspect of the present invention relates to a method for preparing a recombinant microorganism for producing a hydrophobic substance, the method comprising engineering the cell membrane by at least one of the following: inhibition of at least one of cell morphology-related genes and outer membrane vesicle-related genes, and overexpression or introduction of inner membrane vesicle-related genes.

[0107] In the present invention, the cell membrane engineering step is further characterized by the increase in the expression of lipid synthase genes.

[0108] For example, when the microorganism is Escherichia coli, the increase in the expression of the lipid synthase gene may be an additional overexpression of the plsBC gene.

[0109] In the present invention, the recombinant microorganism prepared by the above method can exhibit at least one of the following characteristics: increased cell surface area, increased formation and secretion of outer membrane vesicles, and increased formation of inner membrane vesicles.

[0110] The recombinant microorganism prepared by the method of the present invention has at least one of the following characteristics: increased cell surface area, increased formation and secretion of outer membrane vesicles, and increased formation of inner membrane vesicles, thereby greatly improving the ability of the recombinant microorganism to produce hydrophobic substances accumulated in the cell membrane.

[0111] In the present invention, the cell morphology-related gene may be, for example, a gene involved in cell division or a gene involved in the synthesis or maintenance of the cytoskeleton / cell wall, but is not limited thereto.

[0112] In the present invention, the gene involved in cell division may be a gene encoding a group of prokaryotic enzymes involved in cell division, the prokaryotic enzyme group including, for example, cell division proteins (such as Fts proteins, etc.) and cell division inhibitors (such as MinC, MinD, etc.), but not limited thereto.

[0113] In the present invention, the genes involved in the synthesis or maintenance of the cytoskeleton / cell wall may be genes encoding a prokaryotic enzyme group, the prokaryotic enzyme group including, for example, penicillin binding protein (PBP), cell shape determining protein (MreB, MreC, etc.), peptidoglycan D,D-transpeptidase (MrdA, PbpA, etc.), peptidoglycan glycosyltransferase (MrdB, etc.), cytoskeleton protein (RodZ, etc.), etc., but are not limited thereto.

[0114] For example, when the recombinant microorganism is Escherichia coli, the cell morphology-related gene can be selected from rodZ (cytoskeleton protein), ftsA (cell division protein), ftsB (cell division protein), ftsI (peptidoglycan D, D-transpeptidase), ftsL (cell division protein), ftsQ (cell division protein), ftsW (possible peptidoglycan glycosyltransferase), ftsZ (cell division protein), minD (septum site determining protein), mrdA (peptidoglycan D, D-transpeptidase), mrdB (peptidoglycan glycosyltransferase), mreB (cell shape determining protein), mreC (cell shape determining protein), zipA (cell division protein), murE (UDP-N-acetylmuramoyl-L-alanyl-D-glutamate-2,6-diaminopimelate ligase), pbpC (penicillin binding protein 1C) and combinations thereof, but are not limited thereto. In the present invention, when deoxypurpurogenin is produced, it is most preferred to inhibit the expression of the mrdB gene.

[0115] In the present invention, any outer membrane vesicle-related gene may be included without limitation as long as it is a gene capable of enhancing the formation and secretion of outer membrane vesicles when inhibited, and the outer membrane vesicle-related gene may be easily selected according to the type of recombinant microorganism used.

[0116] In the present invention, the outer membrane vesicle-related gene may be an outer membrane / peptidoglycan structure maintenance-related gene, an outer membrane protein expression gene or a cell membrane metabolic network-related gene, but is not limited thereto.

[0117] In the present invention, the outer membrane / peptidoglycan structure maintenance-related genes may be genes encoding a group of prokaryotic enzymes that help maintain the outer membrane / peptidoglycan structure, such as lipoprotein (Lpp), Tol-Pal system proteins (TolB, Pal, TolA, TolR, etc.), lipopolysaccharide core biosynthesis protein, lipopolysaccharide core heptosyltransferase, lipid A biosynthesis lauroyltransferase, etc., but are not limited thereto.

[0118] In the present invention, the outer membrane protein expression gene can be a gene encoding a prokaryotic enzyme group that contributes to the expression of the outer membrane protein, such as outer membrane protein A (OmpA), outer membrane protein C (OmpC), outer membrane protein F (OmpF), OprF (OmpA homolog), envelope protein (RagA, RagB, etc.), etc., but is not limited to this.

[0119] In the present invention, the cell membrane metabolic network related genes may be genes encoding a cell membrane metabolic network enzyme group derived from prokaryotes, such as quinolone signal (PQS), anti-σ-E factor, σ factor H (AlgU), molecular chaperone protease (DegP), etc., but are not limited thereto.

[0120] In one embodiment of the present invention, after preparing a recombinant Escherichia coli expressing a natural pigment, cell membrane engineering is performed by inhibiting the expression of 26 screened outer membrane vesicle-related genes (Table 7). In the present invention, when the recombinant microorganism is Escherichia coli, the outer membrane vesicle-related genes can be selected from rseA (anti-σ-E factor), rseB (σ-E factor regulatory protein), rffD (UDP-N-acetyl-D-mannosamine dehydrogenase), rffC (dTDP-fucosamine acetyltransferase), rffA (dTDP-4-amino-4,6-dideoxygalactose aminotransferase), ompR (DNA binding dual transcriptional regulator), gmhB (D-glycerol-β-D-mannose-heptose-1,7-diphosphate 7-phosphate enzyme), lpxL (lipid A biosynthesis lauroyltransferase), lpxM (lipid A biosynthesis myristoyltransferase), ompA (outer membrane protein), ompC (outer membrane protein), rfaB (lipopolysaccharide 1,6-galactosyltransferase), rfaC (lipopolysaccharide heptosyltransferase 1), rfaD (ADP-L-glycerol-D-mannose-heptose-6-epimerase), rfaE (bifunctional protein HldE), rfaG (lipopolysaccharide core biosynthesis protein), rfaI (lipopolysaccharide 1,3-galactosyltransferase enzyme), rfaJ (lipopolysaccharide 1,2-glucosyltransferase), rfaK (lipopolysaccharide 1,2-N-acetylglucosamine transferase), rfaP (lipopolysaccharide core heptose (I) kinase), rfaQ (lipopolysaccharide core heptose (II) kinase), rfbA (glucose-1-phosphate thymidine transferase 1), rffH (glucose-1-phosphate thymidine transferase 2), wzxE (ECA polysaccharide chain length regulatory protein), pnp (polyribonucleotide nucleotidyltransferase), to lA (colicin import membrane protein), tolB (Tol-Pal system periplasmic protein), tolC (outer membrane protein), tolR (biopolymer transporter), nlpI (lipoprotein), nlpD (murein hydrolase activating factor), ompF (outer membrane porin), pal (peptidoglycan-associated outer membrane lipoprotein), degS (serine endoprotease), degP (serine endoprotease), tatC (sec-independent protein translocase protein), lpp (murein lipoprotein) and combinations thereof, but not limited thereto.

[0121] In the present invention, when the recombinant microorganism used to produce a hydrophobic substance is a microorganism that does not have an inner membrane vesicle system, another inner membrane vesicle system gene of a eukaryotic or prokaryotic origin that forms an inner membrane may be introduced. In the present invention, when the recombinant cell used to produce a hydrophobic substance inherently includes an inner membrane vesicle system, the inner membrane vesicle gene of the cell itself may be overexpressed, or another inner membrane vesicle system gene of a eukaryotic or prokaryotic origin may be additionally introduced. In the present invention, the inner membrane vesicle-related gene can be a caveolin system gene or a clathrin-epsin system gene derived from a eukaryotic cell, or can be a mgs-dgs system gene derived from a prokaryotic cell, and more specifically can be selected from cav1 (caveolin-1), cav2 (caveolin-2), cav3 (caveolin-3), EPN1 (epsin1), CLINT1 (epsinR), CLTC (clathrin heavy chain 1), CLTCL1 (clathrin heavy chain 2), CLTA (clathrin light chain A), CLTB (clathrin light chain B), AP180, AP2, almgs (1,2-diacylglycerol 3-glucosyltransferase), aldgs (1,2-diacylglycerol-3-glucose (1-2)-glucosyltransferase producing diglucosyldiacylglycerol) and a combination thereof, but are not limited thereto.

[0122] In the present invention, the recombinant microorganism can be selected from Escherichia coli, Rhizobium, Bifidobacterium, Rhodococcus, Candida, Erwinia, Enterobacter, Pasteurella, Mannheimia, Actinobacillus, Aggregatium, Xanthomonas, Vibrio, Pseudomonas, Azotobacter, Acinetobacter, Ralstonia, Agrobacterium, Rhodobacter, Zymomonas, Bacillus, Staphylococcus, Lactococcus, Streptococcus, Lactobacillus, Clostridium, Corynebacterium, Streptomyces, Bifidobacterium, Cyanobacteria and Bacillus.

[0123] Yet another aspect of the present invention relates to a method for preparing a hydrophobic substance, the method comprising producing a hydrophobic substance by culturing a recombinant microorganism for producing a hydrophobic substance according to the present invention or a recombinant microorganism for producing a hydrophobic substance prepared using the above method; and obtaining the produced hydrophobic substance.

[0124] In the present invention, the step of producing a hydrophobic substance by culturing a recombinant microorganism for producing a hydrophobic substance can be performed without limitation by various conventionally known microorganism culturing methods, and the culturing can be performed by appropriately selecting a culture medium, culturing conditions (temperature, time, physical conditions), etc., depending on the strain, the substance to be produced, etc.

[0125] As used herein, the term "culture" means to cultivate microorganisms to obtain the desired effect, and the desired effect in the present invention is to produce hydrophobic substances. Cultivation can usually be carried out in an incubator with an appropriate culture medium suitable for the microorganisms used and containing at least one simple carbon source and, if necessary, a co-substrate.

[0126] In the present invention, the term "culture" may be used interchangeably with "fermentation" in the sense of producing a hydrophobic substance by culturing a microorganism.

[0127] In the present invention, the step of producing the hydrophobic substance by culturing the recombinant microorganism may be performed by fed-batch fermentation.

[0128] As used herein, the terms "fed-batch culture" and "fed-batch fermentation" refer to culture / fermentation in which the concentration of the culture solution is controlled by intermittently additionally supplying a culture medium.

[0129] "Appropriate culture medium" may include a carbon source, a carbon substrate, a nitrogen source (such as peptone), glucose, glycerol, yeast extract, meat extract, malt extract, urea, ammonium sulfate, ammonium chloride, ammonium nitrate or ammonium phosphate, a phosphorus source (such as potassium dihydrogen phosphate or dipotassium hydrogen phosphate), trace elements (such as metal salts) (such as magnesium salts, cobalt salts and / or manganese salts), growth factors such as amino acids and vitamins (which are essential or beneficial nutrients for maintaining and / or growing cells), yeast extract, antibiotics, etc. In the present invention, in order to produce a hydrophobic substance, culture may be carried out within an appropriate temperature range (e.g., 30°C to 40°C, and preferably 35 to 38°C), but the present invention is not limited thereto, and the culture conditions may vary depending on the type of host microorganism, the substance to be expressed, etc.

[0130] The present invention is intended to improve the ability of producing hydrophobic substances accumulated in the cell membrane by increasing the cell membrane area caused by carrying out cell membrane engineering, increasing the formation and secretion of outer membrane vesicles or increasing the formation of inner membrane vesicles. In one embodiment of the present invention, it has been confirmed that the cell membrane area caused by suppressing the expression of cell morphology related genes in Escherichia coli increases, the formation and secretion of outer membrane vesicles caused by suppressing the expression of outer membrane vesicle related genes increases, and the formation of inner membrane vesicles caused by overexpressing inner membrane vesicle related genes increases the ability to produce natural pigments greatly improved, and the natural pigments are representative hydrophobic substances accumulated in the cell membrane. In general, because hydrophobic substances accumulate in the inner membrane and outer membrane of hydrophobic cell membranes or vesicles, it is obvious that the ability of various hydrophobic substances in addition to natural pigments that can be produced by microorganisms can be shown to be improved.

[0131] Therefore, the hydrophobic substance produced by the recombinant microorganism according to the present invention is characterized by accumulation in the cell membrane. Examples of hydrophobic substances may be, but are not limited to, natural pigments, antioxidants, antibiotics, cosmetic additives, anticancer agents, food additives and nutritional supplements.

[0132] In the present invention, natural pigments are pigments or their analogs that are not artificially synthesized but can be obtained from nature, examples of which may include carotenoids, violacein, etc., and specific examples may include but are not limited to lycopene, β-carotene, zeaxanthin, astaxanthin, violacein precursor (PVIO), deoxyviolacein precursor (PDVIO), deoxyviolacein (DVIO), violacein (VIO), etc.

[0133] Examples of antioxidant substances may include, but are not limited to, quercetin, dihydroquercetin, kaempferol, dihydrokaempferol, astaxanthin, resveratrol, tocopherol, tocotrienol, coenzyme Q10, apigenin, and the like.

[0134] Examples of cosmetic additives may include, but are not limited to, aloesin, vitamin A, ceramide, pantothenate, panthenol, lupeol, squalene, eucalyptol, valencene, and the like.

[0135] Examples of food additives may include, but are not limited to, carminic acid, β-carotene, lycopene, and the like.

[0136] Examples of nutritional supplements may include, but are not limited to, silymarin, lutein, vitamins, coenzyme-Q10, resveratrol, omega-3 polyunsaturated fatty acids, ubiquinone, glucosamine, luteolin, and the like.

[0137] In one embodiment of the present invention, it was confirmed that a recombinant microorganism for producing a hydrophobic substance according to the present invention was prepared by suppressing, introducing or overexpressing various genes as described above, and its overall ability to produce a hydrophobic substance was maintained or significantly improved, but the cell membrane engineering of the gene combination showing the most obvious effect of enhancing the production ability differed depending on the hydrophobic substance to be produced.

[0138] Since hydrophobic substances exhibit accumulation in cell membranes, that is, they are hydrophobic, the recombinant microorganism of the present invention that undergoes cell membrane engineering to increase cell membrane area, increase the formation and secretion of outer membrane vesicles, and increase the formation of inner membrane vesicles can exhibit an improved ability to produce hydrophobic substances.

[0139] Therefore, the microorganism for producing a hydrophobic substance that has undergone cell membrane engineering of the present invention can be constructed into a library by suppressing, introducing or overexpressing various gene combinations, and from the perspective of cost, procedures and time for selecting and developing a recombinant strain with an improved ability to produce a hydrophobic substance, it is useful to screen a strain showing a high ability to produce a specific hydrophobic substance using the library.

[0140] Therefore, another aspect of the present invention relates to a microbial library for producing hydrophobic substances, which is obtained by performing cell membrane engineering in a microorganism for producing hydrophobic substances by at least one of the following: inhibition of expression of genes related to cell morphology, inhibition of expression of genes related to outer membrane vesicles, and introduction or overexpression of genes related to inner membrane vesicles.

[0141] Yet another aspect of the present invention relates to a method for screening recombinant microorganisms that have undergone cell membrane engineering and have an improved ability to produce specific hydrophobic substances, the method comprising (a) constructing a microbial library for producing hydrophobic substances by performing cell membrane engineering in the microorganisms for producing hydrophobic substances by at least one of the following: inhibition of expression of cell morphology-related genes, inhibition of expression of outer membrane vesicle-related genes, and introduction or overexpression of inner membrane vesicle-related genes; and (b) selecting recombinant microorganisms with high ability to produce specific hydrophobic substances by culturing the microorganisms for producing hydrophobic substances.

[0142] In the present invention, a microbial library for producing hydrophobic substances having characteristics such as increased cell membrane area, increased formation and secretion of outer membrane vesicles and / or increased formation of inner membrane vesicles can be produced in the following manner: utilizing the phenomenon of accumulation of hydrophobic substances in cell membranes, performing cell membrane engineering by inhibiting or overexpressing the relevant genome; and based on this, recombinant strains with improved ability to produce specific hydrophobic substances can be screened.

[0143] In the present invention, the "library of microorganisms for producing hydrophobic substances" can be obtained by performing the following alone or in any combination: inhibition of expression of genes related to cell morphology, inhibition of expression of genes related to outer membrane vesicles, and introduction or overexpression of genes related to inner membrane vesicles.

[0144] In the present invention, an additional feature of the cell membrane engineering in step (a) may be to increase the expression of lipid synthase genes in the microbial library for producing hydrophobic substances.

[0145] In the present invention, the library may include all recombinant microorganisms in which the expression of cell morphology-related genes is suppressed individually or in any combination.

[0146] In the present invention, cell morphology-related genes may include any gene involved in maintaining cell morphology.

[0147] In the present invention, any cell morphology-related gene may be included without limitation, as long as it is a gene that can increase the cell area by changing the cell morphology when its expression is inhibited, and the gene can be easily selected by those skilled in the art according to the type of recombinant microorganism used.

[0148] In the present invention, the cell morphology-related gene may be, for example, a gene involved in cell division or a gene involved in the synthesis or maintenance of the cytoskeleton / cell wall, but is not limited thereto.

[0149] In the present invention, the gene involved in cell division may be an endogenous gene encoding a prokaryotic enzyme group, such as a cell division protein (eg, Fts protein, etc.) or a cell division inhibitor (eg, MinC, MinD, etc.), but is not limited thereto.

[0150] In the present invention, the genes involved in the synthesis or maintenance of the cytoskeleton / cell wall can be endogenous genes encoding a prokaryotic enzyme group, such as penicillin binding protein (PBP), cell shape determining protein (MreB, MreC, etc.), peptidoglycan D, D-transpeptidase (MrdA, PbpA, etc.), peptidoglycan glycosyltransferase (MrdB, etc.), cytoskeleton protein (RodZ, etc.), etc., but are not limited to these.

[0151] In the present invention, for example, when the recombinant microorganism used to prepare the library is Escherichia coli, the cell morphology-related genes can be selected from rodZ (cytoskeleton protein), ftsA (cell division protein), ftsB (cell division protein), ftsI (peptidoglycan D, D-transpeptidase), ftsL (cell division protein), ftsQ (cell division protein), ftsW (possible peptidoglycan glycosyltransferase), ftsZ (cell division protein), minD (septum site determining protein), mrdA (peptidoglycan D, D-transpeptidase), mrdB (peptidoglycan glycosyltransferase), mreB (cell shape determining protein), mreC (cell shape determining protein), zipA (cell division protein), murE (UDP-N-acetylmuramoyl-L-alanyl-D-glutamate-2,6-diaminopimelate ligase), pbpC (penicillin binding protein 1C) and combinations thereof, but are not limited thereto.

[0152] In the present invention, the library may include all recombinant microorganisms in which the expression of outer membrane vesicle-related genes is suppressed individually or in any combination.

[0153] In the present invention, any outer membrane vesicle-related gene may be included without limitation, as long as it is a gene involved in the formation or secretion of outer membrane vesicles.

[0154] In the present invention, the outer membrane vesicle-related gene may be a gene that plays a role in maintaining the connection between the outer membrane and the inner membrane of a cell or the peptidoglycan layer of a cell.

[0155] In the present invention, the outer membrane vesicle-related gene may be an outer membrane / peptidoglycan structure maintenance-related gene, an outer membrane protein expression gene or a cell membrane metabolic network-related gene, but is not limited thereto.

[0156] In the present invention, the outer membrane / peptidoglycan structure maintenance-related genes may be genes encoding a group of prokaryotic enzymes that help maintain the outer membrane / peptidoglycan structure, such as lipoprotein (Lpp), Tol-Pal system proteins (TolB, Pal, TolA, TolR, etc.), lipopolysaccharide core biosynthesis protein, lipopolysaccharide core heptosyltransferase, lipid A biosynthesis lauroyltransferase, etc., but are not limited thereto.

[0157] In the present invention, the outer membrane protein expression gene can be a gene encoding a prokaryotic enzyme group that contributes to the expression of the outer membrane protein, such as outer membrane protein A (OmpA), outer membrane protein C (OmpC), outer membrane protein F (OmpF), OprF (OmpA homolog), envelope protein (RagA, RagB, etc.), etc., but is not limited to this.

[0158] In the present invention, the cell membrane metabolic network related genes may be genes encoding a cell membrane metabolic network enzyme group derived from prokaryotes, such as quinolone signal (PQS), anti-σ-E factor, σ factor H (AlgU), molecular chaperone protease (DegP), etc., but are not limited thereto.

[0159] In the present invention, for example, when the recombinant microorganism is Escherichia coli, the outer membrane vesicle-related gene can be selected from rseA (anti-σ-E factor), rseB (σ-E factor regulatory protein), rffD (UDP-N-acetyl-D-mannosamine dehydrogenase), rffC (dTDP-fucosamine acetyltransferase), rffA (dTDP-4-amino-4,6-dideoxygalactose aminotransferase), ompR (DNA binding dual transcriptional regulator), gmhB (D-glycero-β-D-mannose-heptose-1,7-diphosphate 7- phosphatase), lpxL (lipid A biosynthesis lauroyltransferase), lpxM (lipid A biosynthesis myristoyltransferase), ompA (outer membrane protein), ompC (outer membrane protein), rfaB (lipopolysaccharide 1,6-galactosyltransferase), rfaC (lipopolysaccharide heptosyltransferase 1), rfaD (ADP-L-glycerol-D-mannose-heptose-6-epimerase), rfaE (bifunctional protein HldE), rfaG (lipopolysaccharide core biosynthesis protein), rfaI (lipopolysaccharide 1,3-galactosyltransferase), transferase), rfaJ (lipopolysaccharide 1,2-glucosyltransferase), rfaK (lipopolysaccharide 1,2-N-acetylglucosamine transferase), rfaP (lipopolysaccharide core heptose (I) kinase), rfaQ (lipopolysaccharide core heptose (II) kinase), rfbA (glucose-1-phosphate thymidine transferase 1), rffH (glucose-1-phosphate thymidine transferase 2), wzxE (ECA polysaccharide chain length regulatory protein), pnp (polyribonucleotide nucleotidyltransferase), t olA (colicin import membrane protein), tolB (Tol-Pal system periplasmic protein), tolC (outer membrane protein), tolR (biopolymer transporter), nlpI (lipoprotein), nlpD (murein hydrolase activating factor), ompF (outer membrane porin), pal (peptidoglycan-associated outer membrane lipoprotein), degS (serine endoproteinase), degP (serine endoproteinase), tatC (sec-independent protein translocase protein), lpp (murein lipoprotein) and combinations thereof, but not limited thereto.

[0160] In the present invention, the library may include all recombinant microorganisms in which the expression of endomembrane vesicle-related genes is suppressed individually or in any combination.

[0161] In the present invention, any inner membrane vesicle-related gene may be included without limitation, as long as it is a gene involved in the formation of inner membrane vesicles.

[0162] In the present invention, any inner membrane vesicle-related gene can be selected and used without limitation, as long as it is a gene capable of improving the formation of inner membrane vesicles. In the present invention, when the recombinant microorganism used to produce a hydrophobic substance is a microorganism that does not have an inner membrane vesicle system, another inner membrane vesicle system gene of a eukaryotic or prokaryotic origin that forms an inner membrane can be introduced to provide a library.

[0163] In the present invention, when the recombinant microorganism for producing a hydrophobic substance inherently includes an inner membrane vesicle system, an inner membrane vesicle-related gene may be overexpressed, or another inner membrane vesicle system gene of eukaryotic or prokaryotic origin may be additionally introduced.

[0164] In the present invention, the inner membrane vesicle-related gene can be a caveolin system gene or a clathrin-epsin system gene derived from a eukaryotic cell, or can be a mgs-dgs system gene derived from a prokaryotic cell, and can be more specifically selected from cav1 (caveolin-1), cav2 (caveolin-2), cav3 (caveolin-3), EPN1 (epsin1), CLINT1 (epsinR), CLTC (clathrin heavy chain 1), CLTCL1 (clathrin heavy chain 2), CLTA (clathrin light chain A), CLTB (clathrin light chain B), AP180, AP2, almgs (1,2-diacylglycerol 3-glucosyltransferase), aldgs (1,2-diacylglycerol-3-glucose (1-2)-glucosyltransferase producing diglucosyldiacylglycerol) and a combination thereof, but is not limited thereto.

[0165] In the present invention, the microbial library for producing hydrophobic substances may include recombinant microorganisms in which any one gene selected from cell morphology-related genes, outer membrane vesicle-related genes and inner membrane vesicle-related genes or any combination of these genes is inhibited, introduced or overexpressed.

[0166] In the present invention, the microorganism library for producing hydrophobic substances may include microorganisms of a single genus or a single species, and may include a mixture thereof with microorganisms of different genus or species.

[0167] In the present invention, the microbial library for producing hydrophobic substances can include any microorganism selected from Escherichia coli, Rhizobium, Bifidobacterium, Rhodococcus, Candida, Erwinia, Enterobacter, Pasteurella, Mannheimia, Actinobacillus, Aggregatium, Xanthomonas, Vibrio, Pseudomonas, Azotobacter, Acinetobacter, Ralstonia, Agrobacterium, Rhodobacter, Zymomonas, Bacillus, Staphylococcus, Lactococcus, Streptococcus, Lactobacillus, Clostridium, Corynebacterium, Streptomyces, Bifidobacterium, Cyanobacteria, Bacillus and combinations thereof.

[0168] In the present invention, the microbial library for producing hydrophobic substances may be endowed with at least one of the following characteristics: increased cell membrane area, increased formation and secretion of outer membrane vesicles, and increased formation of inner membrane vesicles.

[0169] Example

[0170] The present invention can be better understood by the following examples. However, these examples should not be construed as limiting the present invention, and it is clear to those skilled in the art that various modifications or changes can be made within the spirit and scope of the present invention.

[0171] Example 1: Construction of natural pigment producing strains

[0172] Example 1-1: Construction of carotenoid-producing strains

[0173] Carotenoids are responsible for the red, orange and yellow colors in the visible spectrum. Representative carotenoids are beta-carotene, zeaxanthin and astaxanthin, which have orange, yellow and red colors, respectively. Before constructing E. coli that produces the three types of carotenoids, a strain that produces lycopene, which is their precursor, is first constructed. Since E. coli can produce farnesyl diphosphate through the 1-deoxy-D-xylulose 5-phosphate production pathway, it is necessary to introduce three genes, namely crtE, crtB and crtI, in order to produce lycopene ( Figure 1 ). In order to prevent unnecessary precursor accumulation and balance metabolic flux, various combinations of expression levels of individual genes were screened. The expression level was adjusted by changing the sequence of the 5' untranslated region (5'UTR) (Figure 2A). A 5'UTR sequence library consisting of a total of 16 5'UTR sequences was constructed for each gene using the UTR library design program. The individual gene sets fused with 16 different 5'UTR sequences were combined and introduced into the pTac15K plasmid to construct the pLYC library. To construct the pLYC library, the pTac15K plasmid was first linearized by PCR amplification using primers of [SEQ ID NO: 1] and [SEQ ID NO: 2]. Next, the crtE, crtB and crtI genes were PCR amplified in the pCar184 plasmid using primers of [SEQ ID NO:3] and [SEQ ID NO:4], [SEQ ID NO:5] and [SEQ ID NO:6], and [SEQ ID NO:7] and [SEQ ID NO:8], respectively (Choi et al., Appl. Environ. Microbiol. 2010, 76(10):3097-3105), and then cloned into the linearized pTac15k plasmid by Gibson assembly.

[0174] [Table 1]

[0175] Primers used to construct lycopene-producing strains

[0176]

[0177]

[0178] The constructed pLYC library was introduced into the E. coli WLGB-RPP strain developed by this research team in a previous study, and then 200 colonies with particularly dark colors were selected from the colonies 10 times the size of the pLYC library and then cultured in vitro, and then the produced lycopene was extracted, the absorbance at 474nm was measured, and the results were compared. Among them, the top 10 strains were further cultured in flasks, and the maximum production of lycopene in the LYC79 strain was 23.90 mg / L.

[0179] Based on the selected LYC79 strain, strains producing β-carotene, zeaxanthin and astaxanthin were constructed in the same manner. First, the crtY gene for producing β-carotene from lycopene, crtZ for producing zeaxanthin from β-carotene, and BKT for producing astaxanthin from zeaxanthin were additionally required. For each of these genes, a 5'UTR library consisting of 16 different 5'UTR sequences was constructed and fused to the 5' end of the gene.

[0180] To construct the pBTC library, first, the pTrcCDFS plasmid was linearized by PCR amplification using primers of [SEQ ID NO: 9] and [SEQ ID NO: 10]. In addition, crtY amplified by PCR from the pCar184 plasmid using primers of [SEQ ID NO: 11] and [SEQ ID NO: 12] was cloned into the linearized pTrcCDFS by Gibson assembly. To construct the pZEA library, crtY and crtZ amplified by PCR from pCar184 using primers of [SEQ ID NO: 11] and [SEQ ID NO: 13] and primers of [SEQ ID NO: 14] and [SEQ ID NO: 15] were cloned into the linearized pTrcCDFS by Gibson assembly. To construct the pATX library, trCrBKT (Park et al., Metab. Eng. 2018, 49: 105-115) amplified by PCR using primers of [SEQ ID NO: 16] and [SEQ ID NO: 17] in the pAX1 plasmid was inserted into the SalI / HindIII site of pZEA.

[0181] [Table 2]

[0182] Primers for the construction of strains producing β-carotene, zeaxanthin, and astaxanthin

[0183]

[0184]

[0185] Each of the constructed pBTC, pZEA and pATX libraries was introduced into the LYC79 strain, and 20, 40, and 200 colonies were selected by appearance inspection and then cultured in a test tube. The produced β-carotene, zeaxanthin, and astaxanthin were extracted with acetone, the absorbance was measured at 473, 452, and 475 nm wavelengths, and the production concentration was compared. Here, since the color of astaxanthin cannot be distinguished from the color of its precursor canthaxanthin by the naked eye or by absorbance measurement, the top 50 strains were additionally analyzed by HPLC based on the absorbance measurement results. Flask culture was performed on 3, 5, and 10 strains that produced β-carotene, zeaxanthin, and astaxanthin in the largest amount during test tube culture. BTC1, ZEA20, and ATX68 strains showed the highest production of β-carotene (18.65 mg / L), zeaxanthin (12.67 mg / L), and astaxanthin (14.49 mg / L), respectively, and were selected as the final strains ( FIGS. 2A to 2J ).

[0186] 1-2. Construction of a strain producing violacein analogs

[0187] In addition to carotenoids, to complete the visible spectrum, this research team also produced violacein analogs. Violacein analogs are classified as bisindole pigments, produced by bacteria such as Chromobacterium violaceum and Janthinobacterium lividum, and are known to have various pharmacological effects such as anticancer effects. Therefore, this research team constructed a biosynthetic pathway to produce four types of violacein analogs, namely, deoxyviolacein precursor, violacein precursor, deoxyviolacein, and violacein ( Figure 1 3A), and the color of the substance produced was observed (FIG). Since the present research team had already constructed a strain (IND5 containing pTacGEL) that overproduces tryptophan, a common precursor of violacein analogs, through previous research, the violacein analog biosynthesis pathway based on the pTacCDFS vector was introduced into the plasmid of the corresponding strain to prepare a basic strain that produces violacein analogs.

[0188] First, using the pTacCDFS plasmid as the base vector, an inverse PCR reaction was performed using primers of [SEQ ID NO: 18] and [SEQ ID NO: 19] to linearize the plasmid. Thereafter, the vioAB gene was divided into two gene fragments and amplified. The first fragment was amplified using [SEQ ID NO: 20] and [SEQ ID NO: 21], and the second fragment was amplified using [SEQ ID NO: 22] and [SEQ ID NO: 23]. The two DNA fragments were cloned using the linearized plasmid and Gibson assembly to prepare the pTacCDFS-vioAB plasmid. In addition, the pTacCDFS-vioC, pTacCDFS-vioD, pTacCDFS-vioCD, and pTacCDFS-vioE plasmids were constructed using the same method. The vio C, vioD, vioCD and vioE genes were PCR amplified using the corresponding primer pairs [SEQ ID NO:24] and [SEQ ID NO:25], [SEQ ID NO:26] and [SEQ ID NO:27], [SEQ ID NO:24] and [SEQ ID NO:27], and [SEQ ID NO:28] and [SEQ ID NO:29]. The pPDVIO (pTacCDFS-vioABE) plasmid for producing deoxyviolacein precursor (PDVIO) was constructed as follows. Using the pTacCDFS-vioE plasmid as a template, the vioE gene fragment was amplified using primers of [SEQ ID NO:30] and [SEQ ID NO:31] and then inserted into the Sad site in the pTacCDFS-vioAB plasmid. The pPVIO (pTacCDFS-vioABDE), pDVIO (pTacCDFS-vioABCE) and pVIO (pTacCDFS-vioABCDE) plasmids for producing violacein precursor (PVIO), deoxyviolacein (DVIO) and violacein (VIO), respectively, were constructed as follows. The pTacCDFS-vioC, pTacCDFS-vioD and pTacCDFS-vioCD plasmids were used as templates, and the common primers of [SEQ ID NO: 32] and [SEQ ID NO: 31] were used to amplify the gene fragments vioC, vioD and vioCD. The amplified genes were inserted into the SacI site of the pTacCDFS-vioABE plasmid to complete the pDVIO (pTacC DFS-vioABCE), pPVIO (pTacCDFS-vioABDE) and pVIO (pTacCDFS-vioAB CDE) plasmids.

[0189] [Table 3]

[0190] Primers used to construct a strain producing violacein analogs

[0191]

[0192]

[0193] For the flask culture of the violacein producing strain using glucose or glycerol as a carbon source, a higher concentration of violacein is produced when glycerol is used as a carbon source, as shown in Figure 3B. Therefore, all violacein analogs utilize glycerol as a carbon source. From the strain constructed as above, 1.09 g / L of deoxyviolacein is produced when the vioABCE biosynthetic gene cluster (BGC) is introduced, and 1.36 g / L of violacein and 0.13 g / L of deoxyviolacein are produced when vioABCDE BGC is introduced (Figure 3D). When vioABE BGC is introduced, deoxyviolacein precursor is produced, and when vioABDE BGC is introduced, violacein precursor is produced. Since there is no standard substance of violacein precursor and deoxyviolacein precursor, they are purified by the fraction collector attached to HPLC, and their concentration is calculated based on the HPLC calibration table.

[0194] Flask culture conditions were as follows. For carotenoid-producing strains, colonies were inoculated into 3 mL of TB (terrific broth; 20 g tryptone, 24 g yeast extract, 4 mL glycerol, 0.017 M KH2PO4, and 0.072 M K2HPO4 per liter) medium supplemented with appropriate concentrations of antibiotics, followed by culture at 30°C. When the OD of the culture solution reached 600 When the OD reached 1-2, 1 mL of the culture was subcultured in a 250 mL round-bottom flask containing 20 mL of TB medium and cultured until OD 600Reach 1-2. For purple bacteriocin analogs, the colony was inoculated into 10 mL of LB medium supplemented with antibiotics at an appropriate concentration, followed by culturing at 37°C overnight. Thereafter, the prepared carotenoid or purple bacteriocin analog culture solution was transferred to a 250 mL baffled flask containing 50 mL of R / 2 medium supplemented with 3 g / L yeast extract and 20 g / L glycerol (3 g / L (NH4)2SO4 was also added for purple bacteriocin analogs), followed by culturing at 30°C and 200 rpm. R / 2 medium (pH 6.8) had the following composition (per liter): 2 g (NH4)2HPO4, 6.75 g KH2PO4, 0.85 g citric acid, 0.7 g MgSO4·7H2O, and 5 ml trace metal solution (TMS) [10 g FeSO4·7H2O, 2.25 g ZnSO4·7H2O, 1 g CuSO4·5H2O, 0.5 g MnSO4·5H2O, 0.23 g Na2B4O7·10H2O, 2 g CaCl2·2H2O, and 0.1 g (NH4)6Mo7O 24 / L 5M HCl]. When the OD of the culture medium 600 When the pH reached 0.6-0.8, 1 mM isopropyl β-D-1-thiogalactopyranoside (IPTG) was added to induce the expression of the foreign gene. After induction, the culture was carried out for 36 hours for carotenoids and 48 hours for violacein analogs.

[0195] After cultivation, the production amount was analyzed under the following conditions. For carotenoids, cells were collected by centrifuging 1 mL of culture solution, the supernatant was removed, 1 mL of acetone was added, and the substances in the cells were extracted by vigorous vortexing at 55 ° C and 1,500 rpm. The cell debris in the extract was filtered using a centrifuge to obtain a carotenoid extract of the supernatant. For purple bacteriocin analogs, 50 μL of culture solution (the volume of the culture solution added can be appropriately adjusted according to the estimated concentration range; the amount of DMSO added is adjusted so that the total volume is 1 mL) was mixed with 950 μL of dimethyl sulfoxide (DMSO), and then vortexed vigorously at 40 ° C and 1,500 rpm to extract substances inside and outside the cells. Thereafter, the cell debris in the extract was filtered using a centrifuge in the same manner as above, thereby obtaining a purple bacteriocin analog extract of the supernatant. Each extract was quantitatively analyzed using HPLC. In the case of purple bacteriocin analogs, LC-MS (Figures 3E to 3F) was performed because there was no standard substance.

[0196] Example 2. Increasing the production of iridescent pigments by cell morphology engineering

[0197] Carotenoids with long carbon chains and violacein analogs with hydrophobic carbocyclic rings are hydrophobic. Due to these characteristics, when carotenoids and violacein analogs are produced in Escherichia coli, they accumulate in cells, particularly in cell membranes, rather than being released from cells. Therefore, attempts have been made to increase the capacity by increasing the cell membrane area so as to produce a large amount of corresponding substances. For this reason, attempts have been made to suppress the expression of genes responsible for cell membrane-related metabolic networks. In order to suppress the expression of target genes, synthetic regulatory sRNA tools (Na et al., Nat. Biotechnol. 2013, 31 (2): 170-174) have been utilized. As expression inhibition targets, 16 genes involved in cell division and cell morphology maintenance (Table 4) were selected. Expression inhibition target genes were selected according to two criteria, and the first criterion was genes involved in cell division (ftsABILQWZ, minD, zipA). It is expected that inhibition of cell division will change cell length (Fig. 4A). The second criterion is genes involved in cell wall synthesis or maintenance (rodZ, mrdAB, mreBCE, murE). Since the cell wall determines the rod-shaped morphology of E. coli, it is expected that inhibiting the expression of cell wall-related genes will change the cell morphology to be more spherical and more irregular (Figure 4A). In this embodiment, the gene targets considered to be the most effective were selected based on the above two criteria, but the scope of the present invention is not necessarily limited thereto, and other genes corresponding to the above two criteria can also be used as targets.

[0198] [Table 4]

[0199] 16 types of cell morphology-related gene targets

[0200]

[0201] *E, gene essential for the growth of E. coli cells when cultured in minimal medium; NE, gene not essential for the growth of E. coli cells when cultured in minimal medium.

[0202] Most of the target genes are essential genes, so sRNA technology is required. In this experiment, β-carotene producing strains and deoxyviolacein producing strains were typically used for testing, and the results are shown in Figures 4B and 4C.

[0203] As shown in Fig. 4A to Fig. 4J, Fig. 5A and Fig. 5B, in the beta-carotene producing strain, when the expression of cell membrane related genes was suppressed, the change of cell morphology was observed, but the production amount was reduced. On the other hand, in the deoxypurpurogenin producing strain, when the expression of the mrdB gene was suppressed, the production amount increased significantly and reached 1.37g / L (production increased by 25%). When the expression of mrdB was suppressed, as expected, the cell length was shortened and the cell showed a more spherical shape, resulting in a reduction in cell membrane area.

[0204] Example 3. Increasing the production of iridescent pigments by forming inner membrane vesicles

[0205] In order to further increase the amount of rainbow pigment produced, this research team attempted to introduce the inner membrane vesicles present in the eukaryotic cell system, thereby attempting to increase the production of substances accumulated in the membrane by expanding the membrane area in the cell while maintaining the volume of the cell itself (Fig. 4D). In the eukaryotic inner membrane vesicle system, the inner membrane vesicle genes introduced are borrowed from the caveolae, and the caveolae are responsible for the wrinkled shape of the Golgi apparatus or vesicle. First, cav1, cav2 or cav3 genes are introduced into the pTrc99A plasmid, and then introduced into each of the beta-carotene and deoxypurpurogenin producing strains, and then flask culture is carried out. Although the caveolae system of eukaryotic organisms is borrowed in this embodiment, other systems (eukaryotic mesh protein-epsin system, prokaryotic mgs-dgs system, etc.) of the eukaryotic or prokaryotic sources that form the inner membrane also fall within the scope of the present invention.

[0206] Each of the cav1 [SEQ ID NO: 36], cav2 [SEQ ID NO: 37] and cav3 [SEQ ID NO: 38] genes was used after codon optimization of the gene sequence derived from Homo sapiens. To construct the pTrc99A-cav1 plasmid, the cav1 gene was inserted into the EcoRI and BamHI sites of the pTrc99A plasmid. To construct pTrc99A-cav2 and pTrc99A-cav3, the cav2 and cav3 genes were inserted into the NcoI and BamHI sites of the pTrc99A plasmid, respectively. To construct the pTrc99A-cav12 plasmid (containing both cav1 and cav2), the cav2 gene was amplified using primers of [SEQ ID NO: 33] and [SEQ ID NO: 34] and then inserted into the BamHI and PstI sites of the pTrc99A-cav1 plasmid. To construct pTrc99A-cav23 and pTrc99A-cav13, the cav3 gene was amplified using primers of [SEQ ID NO: 35] and [SEQ ID NO: 34] and then inserted into the PstI site of each of the pTrc99A-cav2 and pTrc99A-cav1 plasmids. To construct the pTrc99A-cav123 plasmid, the amplified cav3 gene was inserted into the PstI site of the pTrc99A-cav12 plasmid.

[0207] [Table 5]

[0208] Introduced endomembrane vesicle-related genes and primer sequences

[0209]

[0210]

[0211] The plsBC gene of Escherichia coli was amplified to further supply cell membrane lipids, which may be insufficient due to the formation of the inner membrane structure. To this end, the pTrc99A-plsBC plasmid was first constructed. Therefore, the plsB and plsC genes were amplified from the genomic DNA of Escherichia coli using primers of [SEQ ID NO:39] and [SEQ ID NO:40] and primers of [SEQ ID NO:41] and [SEQ ID NO:42], respectively, and then inserted into the PstI and HindIII sites of the pTrc99A plasmid using Gibson assembly. After the constructed plasmid was cut with PstI and HindIII restriction enzymes, the plsBC gene fragment was separated and inserted into the PstI and HindIII sites of the pTrc99A-cav1 plasmid, thereby constructing the pTrc99A-cav1-plsBC plasmid.

[0212] [Table 6]

[0213] Primers for amplification of cell membrane lipid synthase genes

[0214]

[0215]

[0216] Based on the results, when the cav1 gene was expressed in both the β-carotene and deoxypurpurogenous bacillus producing strains, the production was greatly increased to 21.89 mg / L and 1.28 g / L, respectively. In particular, in the deoxypurpurogenous bacillus producing strain, it was found that when two or three of cav1, cav2 and cav3 were expressed together, the production was greatly reduced (Fig. 4E and Fig. 4F). Based on the results of observing whether the formation of inner membrane vesicles was induced in the control group (Fig. 4G and Fig. 4I) and the cav1 overexpression strain (Fig. 4H and Fig. 4J), TEM (top of each figure) and SEM (bottom of each figure) showed that the inner membrane vesicles were successfully formed in the cav1 overexpression strain, and there was no huge difference in cell morphology relative to the control group.

[0217] Example 4. Increased iridescent pigment production through increased formation and secretion of outer membrane vesicles

[0218] In order to further increase the amount of iridescent pigment produced, the research team attempted to release the iridescent pigment accumulated in the cell through vesicles by increasing the expression of the intrinsic outer membrane vesicle formation genes of the microorganism (Figure 6A). It is reported that for the expression of outer membrane vesicles, it is not important to express specific genes, but to inhibit the expression of genes that play a role in maintaining the connection between the outer membrane and the inner membrane of the cell or the peptidoglycan layer of the cell. Therefore, the research team also attempted to use an sRNA-based target gene expression inhibition system to inhibit the expression intensity of a total of 26 target genes. The 26 expression inhibition gene targets selected are as follows: rseA, rseB, rffD, rffC, rffA, ompR, gmhB, lpxL, ompA, ompC, rfaB, rfaC, rfaD, rfaE, rfaG, rfaI, rfaJ, rfaK, rfaP, rfaQ, rfaY, rfbA, rffH, wzxE and pnp (Table 7). Here, (1) gene targets involved in maintaining the outer membrane / peptidoglycan structure are rfaG, rffA, rffC, rffD, rffH, etc., (2) gene targets corresponding to outer membrane protein expression are ompR, ompC, etc., and (3) gene targets involved in the expression of anti-σ factors in the cell membrane metabolic network are rseA, rseB, etc. In this embodiment, the gene targets considered to be the most effective are selected based on the above three criteria, but the scope of the present invention is not necessarily limited thereto, and other genes corresponding to the above three criteria can also be used as targets. The measurement results of the amount of β-carotene and deoxypurpurogenin produced when the expression of the corresponding gene targets is inhibited are shown in Figures 6B and 6C. When the expression of rfaD, rffD and rfaQ is inhibited, the amount of β-carotene produced is effectively increased to 26.43, 24.21 and 20.29 mg / L, respectively. In particular, when the expression of rfaI and rfaQ is inhibited, the amount of deoxypurpurogenin produced is greatly increased. In the strain in which rfaI expression was suppressed, the production of deoxyviolacein was 1.74 g / L.

[0219] Based on the SEM and TEM results of the BTC1 strain introduced with sRNA that inhibits rffD and rfaD expression and the DVIO strain introduced with sRNA that inhibits rfaI expression, it was observed that the formation and secretion of outer membrane vesicles increased significantly (Figure 6D to Figure 6F). In particular, when the DVIO strain introduced with sRNA that inhibits rfaI expression was cultivated, it was found that outer membrane vesicles, deoxypurpurogenin and cell debris were gathered on the flask wall. Its micrograph is shown in Figure 7E.

[0220] [Table 7]

[0221] 26 gene targets involved in outer membrane vesicles for increasing the formation and secretion of outer membrane vesicles

[0222] Target Gene Protein function importance* NCBI ID rseA σE inhibitors NE 947053 rseB σE inhibitors E 947054 r Genes involved in the ECA pathway E 948977 R Genes involved in the ECA pathway NE 948298 r Genes involved in the ECA pathway NE 948296 ompR Response regulators of ompC and ompF NE 947913 gB Genes involved in the LPS pathway NE 944879 Lp Genes involved in the LPS pathway NE 946216 lmX Genes involved in the LPS pathway NE 945143 ompA OMP A NE 945571 oC Outer membrane protein NE 946716 rf Genes involved in the LPS pathway E 948144 rfC Genes involved in the LPS pathway NE 948136 f Genes involved in the LPS pathway NE 948134 rf Genes involved in the LPS pathway NE 947548 rF LPS core biosynthesis; glucosyltransferase NE 948149 i Genes involved in the LPS pathway NE 948143 rF Genes involved in the LPS pathway E 948142 f Genes involved in the LPS pathway E 948147 f Genes involved in the LPS pathway E 948150 QUR Genes involved in the LPS pathway E 948155 f Genes involved in the LPS pathway E 948145 rf Genes involved in the ECA pathway NE 945154 r Genes involved in the ECA pathway E 948299 wxya Endomembrane translocase of ECA components NE 948294 pnp Polynucleotide phosphorylase NE 947672

[0223] *E, gene essential for the growth of E. coli cells when cultured in minimal medium; NE, gene not essential for the growth of E. coli cells when cultured in minimal medium

[0224] Example 5. Confirmation of the synergistic effect of cell morphology change and vesicle formation

[0225] Based on the above results, synergistic effects were evaluated by combining the genetically engineered targets with the best effects in each category.

[0226] The sRNA plasmid cloning for knocking down multiple target genes simultaneously was performed as follows. The first sRNA fragment was PCR amplified using primers of [SEQ ID NO:43] and [SEQ ID NO:44], and the plasmid containing the second sRNA fragment was linearized by inverse PCR using primers of [SEQ ID NO:45] and [SEQ ID NO:46]. The two sRNA-containing fragments thus obtained were combined using Gibson assembly to complete the sRNA plasmid for double knockdown. In order to insert E. coli plsBC into the plasmid containing sRNA, the pTrc99A-plsBC plasmid was used as a template, the plsBC gene was PCR amplified using primers of [SEQ ID NO:47] and [SEQ ID NO:48], and then inserted into the SphI site of the plasmid containing sRNA. In order to insert the cav1 gene into the sRNA-containing plasmid, the gene was inserted into the SphI site of the sRNA-containing plasmid using primers of [SEQ ID NO: 47] and [SEQ ID NO: 49] and using the pTrc99A-cav1 plasmid as a template.

[0227] [Table 8]

[0228] Primers for amplification of cell membrane lipid synthase genes

[0229]

[0230]

[0231] In the β-carotene producing strain, when the expression of the cell membrane metabolic network related genes of Example 2 was suppressed, the increase in the production amount was not confirmed, so the combination of overexpression of the inner membrane vesicle expression gene (cav1) of Example 3 and inhibition of the expression of the outer membrane vesicle expression target gene (rfaD, rffD, rfaD) of Example 4 was applied. First, the expression of different combinations of the three outer membrane vesicle expression target genes was suppressed. When the expression of rfaD and rffD was suppressed at the same time, the amount of β-carotene produced was greatly increased to 34.2 mg / L (Figure 6B). Although the cav1 gene was additionally overexpressed in the corresponding strain to form inner membrane vesicles, the production amount was reduced (Figure 6G).

[0232] In the deoxyviolacein producing strain, a combination of two or three of the cell membrane metabolic network target gene (mrdB) of Example 2, the inner membrane vesicle expression gene (cav1) of Example 3, and the outer membrane vesicle expression target gene (rfaI) of Example 4 was expressed, and the amount of deoxyviolacein produced was observed. Based on the results, in the strain in which rfaI expression was suppressed and cav1 was overexpressed, the production amount of deoxyviolacein was 1.9 g / L, which was evaluated as the largest (Figure 6H).

[0233] Based on the SEM and TEM results of the BTC1 strain introduced with sRNA that inhibits the expression of rffD and rfaD and with cav1-plsBC and the DVIO strain introduced with sRNA that inhibits the expression of rfaI and with cav1, increased formation and secretion of outer membrane vesicles and increased formation of inner membrane vesicles were observed simultaneously ( Figure 6I and Figure 6J ).

[0234] Example 6. Application of cell membrane expansion strategy in the production of different iridescent pigments

[0235] The strategy used in the above embodiment is applied to other hydrophobic pigments to show the multifunctionality of the present invention. Therefore, the most effective cell membrane engineering strategy for increasing the production of beta-carotene (it is a representative carotenoid compound) and deoxypurpurogenin (it is a representative purpurogenin analog compound) is applied to the remaining rainbow pigment in each category. In increasing the production of beta-carotene, the formation of the inner membrane vesicles caused by overexpressing cav1 and plsBC genes at the same time and the formation of the outer membrane vesicles caused by suppressing rffD and rfaD gene expression are effectively improved, and therefore this strategy is applied to ZEA20 and ATX68 as the strain producing zeaxanthin and astaxanthin. According to its test result, the formation of inner membrane vesicles reduces the production of zeaxanthin, but slightly increases the production of astaxanthin. On the other hand, the formation of outer membrane vesicles increases the production of both zeaxanthin and astaxanthin (respectively 18.38mg / L in Fig. 7 H and 22.69mg / L in Fig. 7 I). For the violacein analogs, the simultaneous expression of inner membrane vesicles and outer membrane vesicles resulted in the highest deoxyviolacein production, so the effect was evaluated by expressing inner membrane vesicles and outer membrane vesicles separately or simultaneously. Therefore, three strategies were tested: (1) rfaI knocked down for overexpression of outer membrane vesicles, (2) cav1 overexpression for overexpression of inner membrane vesicles and (3) rfaI knocked down and cav1 overexpression. When inner membrane vesicles and outer membrane vesicles were expressed simultaneously, the maximum amount of violacein precursor and violacein (402 mg / L in Figure 7K and 2.84 g / L in Figure 7L) were produced. However, when only outer membrane vesicles were expressed, the maximum amount of deoxyviolacein precursor (341 mg / L in Figure 7J) was produced. Here, commercially available reagents for violacein precursor and deoxyviolacein precursor could not be purchased, so the corresponding substances were purified and then quantified using a fraction collector connected to an HPLC device.

[0236] Example 7. Development of a fed-batch fermentation process for efficient production of iridescent pigments

[0237] Use the recombinant Escherichia coli strain constructed in the above embodiment to carry out batch feed fermentation in 6.6L fermentor. Carry out batch feed fermentation under the following conditions.Carotenoids are produced in 6.6L fermentor (BioFlo 320, Eppendorf) and cultivated, and the fermentor is supplemented with 1.6LR / 2 substratum (pH 6.95) containing 30g / L glucose or glycerol, 3g / L yeast extract and antibiotic.Purple bacterium analogs are produced in 6.6L fermentor (BioFlo 320, Eppendorf) and cultivated, and the fermentor is supplemented with 1.95LR / 2 substratum (pH 6.8) containing 20g / L glucose or glycerol, 3g / L yeast extract, 3g / L (NH ) 2SO 4 and antibiotic.Carotenoids are produced in TB substratum containing appropriate concentration of antibiotic by colony inoculation to 3mL, and then cultivated at 30 ℃. For violacein analogs, the colony was inoculated into 10 mL of LB medium supplemented with antibiotics at appropriate concentrations, and then cultured overnight at 37°C. Thereafter, the prepared carotenoid or violacein analog culture solution was transferred to a 250 mL baffled flask containing 50 mL of R / 2 medium supplemented with 3 g / L yeast extract and 20 g / L glycerol or glucose (3 g / L (NH4)2SO4 was also added for violacein analogs), and then cultured at 30°C and 200 rpm. Here, the culture was continued until OD 600 Reach 3-4, and inoculate the culture broth in the fermentor. The pH is maintained at 6.8 using a 28% (v / v) ammonia solution, and the temperature is maintained at 30°C. The dissolved oxygen (DO) value is maintained at 40% by providing air at 2L / min, automatically adjusting the stirring speed to 1,000rpm, and increasing the oxygen flow rate. A pH steady-state strategy is used for nutrient supply, and when the pH value exceeds 7 for carotenoids and exceeds 6.85 for purple bacteriocin derivatives, the feed flow is automatically allowed. The feed solution for the production of carotenoids has the following components per 1L: 800g glucose or 817g glycerol, 6mL trace metal solution, and 12gMgSO4·7H2O. The feed solution for the production of purple bacteriocin derivatives has the following components per 1L: 650g glucose or 800g glycerol, 6mL trace metal solution, 85g (NH4)2SO4 and 8g MgSO4·7H2O. After inoculation, when OD 600 When the cell culture medium reached 20-30 ng / mL, 1 mM IPTG was used to induce the expression of foreign proteins.

[0238] The concentration of each pigment obtained by the fed-batch culture of the recombinant E. coli that showed the maximum production capacity for each pigment was as follows:

[0239] i) Astaxanthin-producing recombinant microorganism ATX68 (pWAS, rffD, rfaD expression inhibition): 322 mg / L ( FIG8A );

[0240] ii) β-carotene-producing recombinant microorganism BTC1 (pWAS, rffD, rfaD expression inhibition): 343 mg / L ( Figure 8B );

[0241] iii) Zeaxanthin-producing recombinant microorganism ZEA20 (pWAS, rffD, rfaD expression inhibition): 218 mg / L ( Figure 8C );

[0242] iv) Viola bacteriocin precursor-producing recombinant microorganism PVIO (pWAS, rfaI expression inhibition and cav1 overexpression): 1.3 g / L ( Figure 8D );

[0243] v) Deoxypurpurogenin precursor-producing recombinant microorganism PDVIO (pWAS, rfaI expression inhibition): 0.855 g / L ( Figure 8E );

[0244] vi) Violentibactin-producing recombinant microorganism VIO (pWAS, rfaI expression suppression and cav1 overexpression: produced 6.69 g / L violentibactin (also produced 1.39 g / L deoxyvioletibactin) ( FIG. 8F ); and

[0245] vii) Deoxyviolacein production by recombinant microorganism DVIO (pWAS, rfaI expression inhibition and cav1 overexpression): 11.3 g / L ( FIG8G ).

[0246] All seven hydrophobic pigments were able to be produced at high concentrations using the E. coli strain developed according to the present invention, which indicates that the present invention is effective for the efficient production of hydrophobic substances.

[0247] Practicality

[0248] According to the present invention, the cell membrane engineering method is roughly divided into three methods: first, changing the cell morphology by inhibiting the expression of genes involved in cell division; second, expanding the inner membrane structure by introducing or overexpressing genes involved in the expression of inner membrane vesicles; and third, overproducing outer membrane vesicles by inhibiting the expression of target genes involved in cell membrane metabolism so as to express outer membrane vesicles.

[0249] These three methods show synergistic effect when used alone or in combination, and they can be used for efficiently producing insoluble hydrophobic substances. The recombinant microorganism used for efficiently producing carotenoids or purple bacteriocin analogs developed by the method for recombinant microorganisms with high ability to produce hydrophobic substances according to the screening of the present invention can be used as the microorganism for producing natural pigments. And the natural pigment production technology developed in the present invention has achieved a significant improvement in production ability. Therefore, the present invention can be effectively applied to the preparation of recombinant strains and the establishment of efficient preparation methods for the efficient production of multiple industrial and medically useful metabolites.

[0250] Although the specific embodiments of the present invention have been disclosed in detail as described above, it is clear to those skilled in the art that the description is only a preferred exemplary embodiment and should not be interpreted as limiting the scope of the present invention. Therefore, the true scope of the present invention will be defined by the appended claims and their equivalents. Sequence Listing <110> KAIST <120> Recombinant microorganisms having improved ability to produce hydrophobic substances and cell membrane engineering methods for preparing the same <130> PF-B2656 <150> KR 10-2020-0144521 <151> 2020-11-02 <160> 49 <170> PatentIn version 3.5 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> pTac15K plasmid primer-Forward <400> 1 cttggctgtt ttggcggatg 20 <210> 2 <211> 29 <212> DNA <213> Artificial Sequence <220> <223> pTac15K plasmid primer-reverse <400> 2 tgtttcctgt gtgaaattgt tatccgctc 29 <210> 3 <211> 69 <212> DNA <213> Artificial Sequence <220> <223> crtE Primer-Forward <400> 3 ataacaattt cacacaggaa acacgytcmg cggaaagrag catcgwccat gtatccgttt 60 ataaggaca 69 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> crtE Primer - Reverse <400> 4 ttaactgacg gcagcgagtt 20 <210> 5 <211> 61 <212> DNA <213> Artificial Sequence <220> <223> crtB Primer - Forward <400> 5 cgctgccgtc agttaaarcc ttgttcaaag gmsyatctag gatgaataat ccgtcgttac 60 t 61 <210> 6 <211> 30 <212> DNA <213> Artificial Sequence <220> <223> crtB Primer - Reverse <400> 6 ttcgaacggt tcttagagcg ggcgctgcca 30 <210> 7 <211> 52 <212> DNA <213> Artificial Sequence <220> <223> crtI Primer-Forward <400> 7 gctctaagaa ccgttcgaaw gsagcrtmca agatgaaacc aactacggta at 52 <210> 8 <211> 35 <212> DNA <213> Artificial Sequence <220> <223> crtI Primer - Reverse <400> 8 cgccaaaaca gccaagttaa atcagatcct ccagc 35 <210> 9 <211> 18 <212> DNA <213> Artificial Sequence <220> <223> pTrcCDFS plasmid primer - forward <400> 9 tctagagtcg acctgcag 18 <210> 10 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> pTrcCDFS Plasmid Primer - Reverse <400> 10 tctgtttcct gtgtgaaatt 20 <210> 11 <211> 61 <212> DNA <213> Artificial Sequence <220> <223> crtY Primer-Forward <400> 11 caatttcaca caggaaacag accttcctcc awaagragca tcmastatgg gagcggctat 60 g 61 <210> 12 <211> 36 <212> DNA <213> Artificial Sequence <220> <223> crtY Primer 1 - Reverse <400> 12 gcaggtcgac tctagattaa cgatgagtcg tcataa 36 <210> 13 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> crtY Primer 2 - Reverse <400> 13 ttaacgatga gtcgtcataa 20 <210> 14 <211> 67 <212> DNA <213> Artificial Sequence <220> <223> crtZ Primer-Forward <400> 14 cattatgacg actcatcgtt aaagtacatc cgammgsagc atccttkatg ttgtggattt 60 ggaatgc 67 <210> 15 <211> 31 <212> DNA <213> Artificial Sequence <220> <223> crtZ Primer - Reverse <400> 15 gcaggtcgac tctagattac ttcccggatg c 31 <210> 16 <211> 52 <212> DNA <213> Artificial Sequence <220> <223> trCrBKT Primer-Forward <400> 16 agacaggtcg ackccacccc gcaaaggags atcgkcratg ggtccgggca tc 52 <210> 17 <211> 27 <212> DNA <213> Artificial Sequence <220> <223> trCrBKT Primer - Reverse <400> 17 agacagaagc ttttacgcca gcgccgc 27 <210> 18 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> pTacCDFS plasmid primer - forward <400> 18 tggaattcga gctcggtacc 20 <210> 19 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> pTacCDFS Plasmid Primer - Reverse <400> 19 ttcacacagg aaacagacca 20 <210> 20 <211> 42 <212> DNA <213> Artificial Sequence <220> <223> vioAB Primer-Forward <400> 20 cacacaggaa acagaccaat gaagcattct tccgatatct gc 42 <210> twenty one <211> twenty one <212> DNA <213> Artificial Sequence <220> <223> vioAB mid primer - reverse <400> twenty one gccaggcttc ggaatcgaat g 21 <210> twenty two <211> twenty one <212> DNA <213> Artificial Sequence <220> <223> vioAB mid primer - forward <400> twenty two cattcgattc cgaagcctgg c 21 <210> twenty three <211> 47 <212> DNA <213> Artificial Sequence <220> <223> vioAB Primer - Reverse <400> twenty three ggtaccgagc tcgaattcca ttatcaggcc tctctagaaa gctttcc 47 <210> twenty four <211> 41 <212> DNA <213> Artificial Sequence <220> <223> vioC Primer-Forward <400> twenty four cacacaggaa acagaccaat gaaaagagca atcatagtcg g 41 <210> 25 <211> 45 <212> DNA <213> Artificial Sequence <220> <223> vioC Primer - Reverse <400> 25 ggtaccgagc tcgaattcca ttatcagttg accctcccta tcttg 45 <210> 26 <211> 39 <212> DNA <213> Artificial Sequence <220> <223> vioD Primer-Forward <400> 26 cacacaggaa acagaccaat gaagattctg gtcatcggc 39 <210> 27 <211> 42 <212> DNA <213> Artificial Sequence <220> <223> vioD Primer - Reverse <400> 27 ggtaccgagc tcgaattcca ttatcagcgt tgcagcgcgt ag 42 <210> 28 <211> 38 <212> DNA <213> Artificial Sequence <220> <223> vioE Primer-Forward <400> 28 cacacaggaa acagaccaat ggaaaaccgg gaaccgcc 38 <210> 29 <211> 42 <212> DNA <213> Artificial Sequence <220> <223> vioE Primer - Reverse <400> 29 ggtaccgagc tcgaattcca ttactagcgc ttggcggcga ag 42 <210> 30 <211> 41 <212> DNA <213> Artificial Sequence <220> <223> vioE_frag Primer-Forward <400> 30 cctgataatg gaattcgagc tgactgcacg gtgcaccaat g 41 <210> 31 <211> twenty one <212> DNA <213> Artificial Sequence <220> <223> vioE_frag Primer - Reverse <400> 31 caggtcgact ctagaggatc c 21 <210> 32 <211> 41 <212> DNA <213> Artificial Sequence <220> <223> vio_frag primer-forward <400> 32 gctagtaatg gaattcgagc tgactgcacg gtgcaccaat g 41 <210> 33 <211> 53 <212> DNA <213> Artificial Sequence <220> <223> cav2 Primer - Forward <400> 33 ttaactggat cctttcacac aggaaacaga ccatggggct tgagactgag aag 53 <210> 34 <211> twenty four <212> DNA <213> Artificial Sequence <220> <223> cav Primer - Reverse <400> 34 catccgccaa aacagccaag cttg 24 <210> 35 <211> 53 <212> DNA <213> Artificial Sequence <220> <223> cav3 Primer - Forward <400> 35 ttaactctgc agtttcacac aggaaacaga ccatgatggc cgaagagcat acc 53 <210> 36 <211> 537 <212> DNA <213> Artificial Sequence <220> <223> cav1 gene <400> 36 atgtctgggg gcaaatacgt agactcggag ggacatctct acaccgttcc catccgggaa 60 cagggcaaca tctacaagcc caacaacaag gccatggcag acgagctgag cgagaagcaa 120 gtgtacgacg cgcacaccaa ggagatcgac ctggtcaacc gcgaccctaa acacctcaac 180 gatgacgtgg tcaagattga ctttgaagat gtgattgcag aaccagaagg gacacacagt 240 tttcacggca tttggaaggc cagcttcacc accttcactg tgacgaaata ctggttttac 300 cgcttgctgt ctgccctctt tggcatcccg atggcactca tctggggcat ttacttcgcc 360 attctctctt tcctgcacat ctgggcagtt gtaccatgca ttaagagctt cctgattgag 420 attcagtgca ccagccgtgt ctattccatc tacgtccaca ccgtctgtga cccactcttt 480 gaagctgttg ggaaaatatt cagcaatgtc cgcatcaact tgcagaaaga aatataa 537 <210> 37 <211> 489 <212> DNA <213> Artificial Sequence <220> <223> cav2 gene <400> 37 atggggcttg agactgagaa ggcagatgtc caactgttca tggatgatga ttcttactca 60 catcactcag gactggaata tgcagatcca gaaaagtttg cggactccga ccaggatcgt 120 gacccccacc gcttaaatag tcacttaaaa ctgggctttg aagatgtgat cgcggagcct 180 gtcacaactc atagtttcga taaggtttgg atttgctcac acgcattatt tgaaatttca 240 aagtacgtta tgtataagtt ccttactgta tttttggcca tccctcttgc ctttatcgca 300 ggaatcctgt tcgctacctt gagttgtctg cacatttgga ttcttatgcc attcgtaaag 360 acatgcctta tggtgttgcc atcagtgcaa accatctgga agtccgtcac tgatgtaatt 420 attgcccctt tgtgtacatc tgtgggccgc tgcttttcga gcgtctcact tcaattgtcg 480 caggattaa 489 <210> 38 <211> 456 <212> DNA <213> Artificial Sequence <220> <223> cav3 gene <400> 38 atgatggccg aagagcatac cgatcttgaa gctcaaattg taaaggatat tcattgtaag 60 gaaattgact tggttaatcg tgatcctaag aacatcaacg aggatatcgt taaggtagac 120 ttcgaggatg ttattgcaga acctgttgga acatacagtt tcgacggtgt ctggaaggtg 180 tcgtacacta cgtttaccgt tagtaagtat tggtgctatc gcttactgtc cactctgttg 240 ggtgtccccc ttgctttgct ttggggattc ctgttcgcgt gtatctcttt ttgccatatt 300 tgggctgtcg ttccatgtat taaatcgtac ttaattgaga ttcaatgtat ctctcatatt 360 tatagtcttt gtatccgcac gttctgtaat cccctttttg cggccttggg gcaggtgtgc 420 tcaagtatta aggttgtact tcgtaaggag gtctaa 456 <210> 39 <211> 55 <212> DNA <213> Artificial Sequence <220> <223> plsB Primer - Forward <400> 39 ctagagtcga cctgcagttt cacacaggaa acagaccatg tccggctggc cacga 55 <210> 40 <211> 37 <212> DNA <213> Artificial Sequence <220> <223> plsB Primer - Reverse <400> 40 tctgtttcct gtgtgaaatt acccttcgcc ctgcgtc 37 <210> 41 <211> 59 <212> DNA <213> Artificial Sequence <220> <223> plsC Primer - Forward <400> 41 gaagggtaat ttcacacagg aaacagacca tgctatatat ctttcgtctt attattacc 59 <210> 42 <211> 38 <212> DNA <213> Artificial Sequence <220> <223> plsC Primer 1 - Reverse <400> 42 ccgccaaaac agccaagctt ttaaactttt ccggcggc 38 <210> 43 <211> 41 <212> DNA <213> Artificial Sequence <220> <223> sRNA primer 1-Forward <400> 43 cactagatct caaatgtgct ggaattctaa caccgtgcgt g 41 <210> 44 <211> 43 <212> DNA <213> Artificial Sequence <220> <223> sRNA Primer 1 - Reverse <400> 44 ccttataaat caaacatgtg cggcgaattg ggtacctata aac 43 <210> 45 <211> twenty two <212> DNA <213> Artificial Sequence <220> <223> sRNA primer 2-Forward <400> 45 gcacatgttt gatttataag gg 22 <210> 46 <211> twenty two <212> DNA <213> Artificial Sequence <220> <223> sRNA Primer 2 - Reverse <400> 46 cagcacattt gagatctagt gg 22 <210> 47 <211> 40 <212> DNA <213> Artificial Sequence <220> <223> PTRC Primer - Forward <400> 47 atgtgacagc ttatcgcatg cttgacaatt aatcatccgg 40 <210> 48 <211> 42 <212> DNA <213> Artificial Sequence <220> <223> plsC Primer - Reverse <400> 48 cctgggttta cctaggcatg cttaaacttt tccggcggct tc 42 <210> 49 <211> 43 <212> DNA <213> Artificial Sequence <220> <223> Cav1 Primer - Reverse <400> 49 cctgggttta cctaggcatg ctttatatttc tttctgcaag ttg 43

Claims

1. A recombinant microorganism for producing a hydrophobic pigment, wherein the recombinant microorganism is engineered in the following manner: (i) inhibition of the rfaI (lipopolysaccharide 1,3-galactosyltransferase) gene; (ii) inhibiting the rfaI gene and introducing or overexpressing the cav1 (caveolin-1) gene; (iii) inhibiting rfaD (ADP-L-glycerol-D-mannose-heptose-6-epimerase) and rffD (UDP-N-acetyl-D-mannosamine dehydrogenase) genes; or (iv) Suppression of the rfaD gene and the rffD gene, and introduction or overexpression of the cav1 gene.

2. The recombinant microorganism according to claim 1, wherein the microorganism is selected from the group consisting of Escherichia coli, Rhizobium, Bifidobacterium, Rhodococcus, Candida, Erwinia, Enterobacter, Pasteurella, Mannheimia, Actinobacillus, Aggregatium, Xanthomonas, Vibrio, Pseudomonas, Azotobacter, Acinetobacter, Ralstonia, Agrobacterium, Rhodobacter, Zymomonas, Bacillus, Staphylococcus, Lactococcus, Streptococcus, Lactobacillus, Clostridium, Corynebacterium, Streptomyces, Cyanobacteria and Bacillus.

3. The recombinant microorganism according to claim 1, wherein the hydrophobic pigment is selected from the group consisting of astaxanthin, β-carotene, zeaxanthin, violacein precursor, deoxyviolacein precursor, deoxyviolacein and violacein.

4. The recombinant microorganism according to claim 1, wherein the hydrophobic pigment is a carotenoid pigment, and the expression of rffD and rfaD genes has been suppressed in the recombinant microorganism, and the carotenoid pigment is β-carotene, zeaxanthin or astaxanthin.

5. The recombinant microorganism according to claim 1, wherein the hydrophobic pigment is violacein or an analog thereof, and the expression of the rfaI gene has been inhibited in the recombinant microorganism and the cav1 gene has been introduced or overexpressed in the recombinant microorganism, and the analog of violacein is deoxyviolacein, a violacein precursor or a deoxyviolacein precursor.

6. A method for preparing a hydrophobic substance, the method include: Cultivating the recombinant microorganism according to any one of claims 1 to 5; and The produced hydrophobic pigment is recovered. The method according to claim 6 , wherein the culturing is carried out as a fed-batch culture.

Citation Information

Patent Citations

  • Method and apparatus for voice translation using a multilingual text-to-speech synthesis model

    KR1020200144521A

  • Latency associated peptide and uses therefor

    WO1991008291A2

  • Bacterial cells with improved tolerance to polyamines

    WO2017097828A1

  • Multiplex target gene expression inhibition system based on synthesis regulator srna and method of producing same

    WO2020004936A1